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ABSTRACT
JUSTIN BRANDON COLLIER. Elucidation of ERK1/2 Signaling Pathways
Leading to Mitochondrial Biogenesis. (Under the direction of RICK G.
SCHNELLMANN)

Acute kidney injury (AKI) is a rapid loss of normal kidney function and is
accompanied by a dysregulation of cellular and mitochondrial metabolism, which can
be observed before organ dysfunction. A hallmark of AKI is the early and persistent
disruption of mitochondrial homeostasis. Mitochondrial biogenesis (MB), the process
by which new mitochondria are generated, has been shown to prevent injury and
increase the rate of recovery of ischemia-reperfusion injury (IRI)-induced renal
dysfunction. However, the molecular mechanisms mediating MB and dysfunction
following IRI remain unclear.
We elucidated that extracellular signal-regulated kinase 1/2 (ERK1/2) regulates
two key mitochondrial and cellular metabolism pathways following AKI. The first is
the rapid downregulation of MB through decreased peroxisome proliferator-activated
receptor gamma coactivator-1α (PGC-1α) expression, the master regulator of MB. The
second is nicotinamide adenine dinucleotide (NAD) loss after IRI, particularly the
oxidized form, NAD+.

xiii

Trametinib, an FDA approved drug, prevents ERK1/2 activation by inhibiting
mitogen-activated protein kinase kinase 1/2 (MEK1/2). ERK1/2 inhibition prior to IRI
prevents the downregulation of PGC-1α gene expression. In addition, trametinib
prevented PGC-1α acetylation, which deactivates PGC-1α, after IRI. This was verified
by determining that trametinib inhibited the loss of downstream PGC-1α and MB targets
after IRI, including both nuclear- and mitochondrial-encoded genes.
NAD+ is a vital coenzyme in cellular metabolism, redox signaling, and
contributes to overall cellular health. NAD+ is depleted during injury, and restoration or
prevention of this depletion averts worsening injury and often promotes recovery.
Inhibition of ERK1/2 activation attenuated NAD+ loss and was mediated through
increased nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme
of the NAD+ biosynthetic salvage pathway. Inhibition of renal ERK1/2 activation
decreased miR34a, a known regulator of NAMPT, and led to an increase in NAMPT
protein.
In conclusion, inhibiting ERK1/2 activation restored PGC-1α protein levels,
attenuated the loss of downstream MB targets, increased NAMPT protein, and restored
NAD+ after IRI. These cellular alterations ultimately led to restored kidney function
following IRI-induced AKI. These studies may help support the identification of
potential therapeutic targets for the treatment of AKI.
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CHAPTER ONE:
Review of renal anatomy and physiology, acute kidney injury, mitochondrial
biology and biogenesis, and extracellular signal-regulated kinase 1/2 signaling

1

RENAL ANATOMY AND PHYSIOLOGY
Overview
Normally there are two kidneys working simultaneously in the human body
filtering blood to maintain fluid homeostasis by removing waste products and extra
fluid. The kidney maintains the proper balance of fluid volume, electrolytes (sodium,
potassium), minerals (calcium, phosphorous), and blood pH. By maintaining proper
fluid homeostasis all the other organs are able to function properly. In addition to fluid
homeostasis, the kidneys also serve a critical role in eliminating harmful toxins,
xenobiotics, and waste products (ex. ammonia and urea) that can build up in the
circulatory system, and cause harmful side effects. Two other major contributions to a
healthy functioning body are the control of blood pressure and the production of red
blood cells. Blood pressure is controlled through both fluid homeostasis and through
the secretion of the hormone renin and subsequent renin-angiotensin-aldosterone
signaling pathways. The kidneys contribute to the creation of new red blood cells by
releasing the hormone erythropoietin, which signals the bone marrow to produce more
red blood cells, often as a way to increase oxygen supply to the rest of the body. The
kidney anatomy can typically be divided into three regions (working from outermost
to inner): the renal cortex, the renal medulla (consisting of the outer and inner
medulla), and the renal pelvis. A diagram is provided below (Figure 1.1).
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The Nephron
The kidney consists of around a million nephrons, which are considered the
basic functional unit of the kidney. The nephrons filter, excrete, and reabsorb solutes
and fluid to help maintain fluid and electrolyte balance through complex pressure and
gradient pathways. Blood enters the nephron via the renal artery and into the section of
the nephron called the glomerulus. The glomerulus is the first step in the filtration
process and the filtrate then flows into the renal tubule. The renal tubule is comprised
of the proximal tubule, ascending and descending limbs of the loop of Henle, the distal
tubule, and the collecting duct. A diagram is provided below for further observation
(Figure 1.2).
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Renal Vasculature
Blood from the renal artery enters the glomerulus via the afferent arterioles and
is filtered in the glomerular capillary bed. Blood that passes through the glomerulus
without being filtered exits via the efferent arteriole and consists of larger molecules,
such as various blood cells and higher molecular weight proteins. The efferent blood
continues flowing to supply the renal cortex and the renal medulla and papilla, as well
as allow for the return of water and solutes the tubule filters and reabsorbs. The renal
cortex filters around 90% of the renal blood flow. This disparity in blood flow within
the kidney is due to the cortex consisting of mainly proximal tubules which rely
heavily on oxidative phosphorylation for energy production, which requires more
oxygen availability and therefore more blood flow. The renal medulla and papilla
utilize mainly glycolysis for energy production and requires less oxygen than the
proximal tubules. The small capillaries eventually return to the renal venules to form
segmental renal veins. The renal vein then takes blood away from the kidney that has
now been filtered, reabsorbed, and deoxygenated.
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The Glomerulus
The purpose of the glomerulus is to be the beginning step of the blood
filtration process. The thin walls allow water and waste products to pass through the
glomerulus and into the tubule where further filtration and concentration can occur.
Glomerular filtration can be affected by changes in blood volume, blood pressure, and
vascular tone to the afferent and efferent arterioles. The afferent arteriole blood flows
into the glomerulus and into an area called Bowman’s capsule. Blood is filtered
through various layers of cells and membranes composed of capillary endothelium,
glomerular basement membrane, and podocytes. Podocytes are a specific cell type that
are found on the outside of capillaries inside the Bowman’s capsule. Substances found
in the blood generally are filtered depending on their size and charge. Smaller
molecules can pass through and into the renal tubules, whereas proteins greater than
~60 kDa continue into the efferent arteriole. Smaller proteins that are highly anionic
are potentially limited in their filtration, most likely due to the glomerular basement
membrane also being anionic, causing a repulsion effect. The rate at which blood is
filtered in the glomerulus and the fluid passes into the tubule is termed the glomerular
filtration rate or GFR, and is used as a renal functional diagnostic test in hospitals and
laboratory settings. A person with no kidney disease will typically have a GFR of
greater than 60 mL/min, and a GFR under 60 mL/min is diagnosed with some form of
kidney dysfunction, injury, or disease.
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The Proximal Tubule
The glomerular filtrate passes through the Bowman’s space and into the
proximal tubule, where the filtrate is further filtered. The proximal tubule further
reabsorbs both fluid and electrolytes, including a majority of the water that passes
through the glomerulus. Electrolytes and ions are reabsorbed here by way of ion
transporters, including sodium chloride, potassium, calcium, phosphate, and
bicarbonate, where they enter back into the systemic blood supply. Glucose,
carbohydrates, and various amino acids are also reabsorbed here through active and
facilitated diffusion. As mentioned earlier, the proximal tubules have a high-energy
demand and thus utilize oxidative phosphorylation for ATP production. The
abundance of the various transporters and the activity of reabsorption places a highenergy burden (need for ATP) on the proximal tubules and oxygen demand; which
highlights why the renal cortex receives 90% of the blood supply. The proximal tubule
can be further divided into 3 sections: the S1, S2, and S3 segments. The S1 segment is
where around 90% of the glucose is reabsorbed, and most of the bicarbonate, amino
acids, and other carbohydrates. The S2 and S3 segment reabsorb the remaining
glucose and has organic anion transporters involved in the secretion of various
exogenous compounds, including antibiotics, NSAIDs, methotrexate, etc. The fluid
passes into the Loop of Henle and ultimately into the bladder as urine.
Morphologically, the three segments can be observed to possess different brush border
characteristics.
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Loop of Henle – Distal Tubule – Collecting Duct
The Loop of Henle is a U-shaped section of the nephron, and consists of the
thin descending and ascending limbs and a thick ascending limb. In the descending
limb additional water is reabsorbed, further concentrating the filtrate. As the fluid
enters the ascending limb, sodium chloride is further reabsorbed by diffusion and as
the fluid reaches higher segments of the ascending limb, sodium chloride and
potassium can be actively transported out of the filtrate, if necessary. In a person with
high sodium intake, these transporters will not be utilized to the extent of a person
with very low sodium intake. The remaining sodium chloride is expelled in the urine.
The distal convoluted tubule receives the fluid from the ascending limb and is a major
area of pH regulation. The distal tubule maintains proper pH by absorbing and/or
secreting bicarbonate and protons (H+) into the filtrate. Sodium and potassium can be
further influenced in the distal tubule and is where the thiazide diuretics mechanism of
action is located. Thiazide diuretics inhibit the sodium chloride reabsorption in the
distal tubule by inhibiting the sodium chloride symporter. The fluid passing through
the distal tubule flows into the collecting duct that acts as a connecting region from the
tubules to the minor calyx or renal pelvis. The collecting duct is the final area of
electrolyte and water reabsorption. Normally the collecting duct reabsorbs around 5%
of the sodium and 5% water, however during times of dehydration, and in the presence
of antidiuretic hormones, the collecting duct may reabsorb much more water to
prevent bodily harm due to dehydration. Both aldosterone and vasopressin have
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effects on the collecting duct’s reabsorption and filtration system. Aldosterone
increases sodium and water reabsorption and increases potassium excretion.
Vasopressin increases the amount of water reabsorbed without altering solute
reabsorption by increasing aquaporin channels, ultimately creating urine that is more
concentrated. Fluid remaining in the collecting duct will enter various regions of the
kidney in succession: the minor calyx, major calyx, renal pelvis, ureter, and bladder.
Once in the bladder, the urine can be expelled. A diagram is provided below that
depicts the kidney gross anatomy and inner nephron together with the renal
vasculature (Figure 1.3).
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ACUTE KIDNEY INJURY
Definition and Clinical Classification
Acute kidney injury (AKI) is defined as the rapid and abrupt loss of normal
renal function (usually within less than 7 days). Decreased urine output, electrolyte
and mineral imbalance, improper fluid balance, and an increase of waste products in
the serum are all potential symptoms of AKI. Two of the most well-known waste
products that become elevated are creatinine and urea. An older term for an abrupt loss
of kidney function was acute renal failure (ARF). This term has been phased out in
lieu of AKI, to more properly demonstrate the reality that less severe kidney injury
(i.e. not reaching kidney failure status) can still have a detrimental impact on the
patient’s renal function and overall health. Clinically, a patient will be categorized as
having AKI by their estimated glomerular filtration rate (GFR), which requires their
serum creatinine (SCr) and urine output. The American Journal of Kidney Diseases
and the National Kidney Foundation released 2018 AKI guidelines, titled,
“Management of Acute Kidney Injury: Core Curriculum 2018.” These guidelines
utilized three distinct classification systems (Figure 1.4): 1) Kidney Disease:
Improving Global Outcomes (KDIGO), 2) Acute Kidney Injury Network (AKIN), 3)
Risk, Injury, Failure, Loss, and End-stage renal disease (RIFLE) [1].
The overall comparisons of the three different classifications can be found below in
Figure 1.4, taken from the American Journal of Kidney Diseases and the National
Kidney Foundation 2018 AKI guidelines (Figure 1.4). The RIFLE classification is the
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lone system that contains five different categories versus three for the other
classification systems. RIFLE associates varying degrees of kidney dysfunction to the
five criteria levels:

1) Risk- defined as a ≥ 1.5-fold increase in SCr within 7 days and sustained for ≥ 24 hr
in conjunction with urine output < 0.5 mL/kg/h for 6-12 hr
2) Injury- is a ≥ 2-fold increase in SCr and urine output < 0.5 mL/kg/h for ≥ 12 hr 3)
Failure- is a SCr ≥ 3.0 mg/dL OR SCr increase to ≥ 4.0 mg/dL with an increase to 0.5
mg/dL OR initiation of renal replacement therapy (RRT), in combination with < 0.3
mL/kg/h for ≥ 24 hr or anuria for ≥ 12 hr
4) Loss- is the complete loss of kidney function for > 4 weeks
5) ESKD- is end-stage kidney disease defined as a sustained absence in renal function
for > 3 months.

RIFLE classification is one of the first systems to identify an increase in AKI severity
as an independent determinant for increased mortality [9]. RIFLE is also one of the
better systems for predicting patient outcomes, especially for patients in intensive care
[9-13]. A few limitations are identified for the RIFLE classification system. One
limitation is that a baseline serum creatinine is needed, and this number is routinely
not known. Another limitation is the RIFLE system uses serum creatinine and urine
output as its lone diagnostic markers, which gives no indication of where the injury or
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dysfunction is originating from; in contrast with some of the newer renal injury
biomarkers [9, 14-17]. Regardless, the various classification systems and
standardization for renal dysfunction have allowed for a plethora of controlled studies
to help determine causative correlations with morbidity and mortality, as well as being
a key diagnostic tool for patient prognosis and for therapeutic interventions.
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Figure 1.4: Comparison of Recent Consensus AKI Definitions. Table is
from AJKD’s Core Curriculum 2018 update on Management of Acute
Kidney Injury [1].
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AKI Epidemiology
Because AKI has been defined by various classification systems, and each could use
different functional markers for the level of dysfunction, AKI incidence can vary
significantly within reviews and renal studies. However, a thorough United States
community-based study that followed nearly four million participants estimated the
incidence of non-dialysis-requiring AKI to be approximately 384.1 per 100,000
person-years and the incidence of dialysis-requiring AKI was 24.4 per 100,000
person-years [18]. In the aforementioned study, males and the elderly experienced
AKI at a higher rate than other populations [18]. Another study demonstrated that AKI
incident rates could reach up to 65% in the critical hospitalized patients found in ICU
settings [19]. Besides being an already common disorder in the hospital and ICU
settings, studies suggest that AKI incidence may be increasing [20-22]. The reasons
for this phenomenon range from better reporting, clearer guidelines and rules for
diagnosing, to better overall healthcare for the elderly.
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Morbidity and Mortality Associated with AKI
Mortality has been demonstrated to correlate with increased severity of AKI in
hospitalized patient settings, such as cardiac surgery, major trauma, and critical illness
[12, 23, 24]. In fact, approximately 24% of adults and 14% of children from mainly
developed nations are associated with AKI mortality [2] (Figure 1.5). As one might
expect as patients with higher level of care needed in a hospitalized setting, the
mortality rate increases. Critically ill patients in the intensive care unit, requiring renal
replacement therapy, have mortality rates around 55% [25, 26]. In a study following
US military veterans, found that those with AKI had a long-term mortality rate two
times larger compared to those vets without AKI [27]. As mentioned earlier under
section AKI Epidemiology, reporting of AKI has increased, however, mortality from
AKI is decreasing [10, 28]. Better diagnostics and supportive treatment care are the
most likely reasons for this change in mortality [10, 28]. Morbidity associated with
AKI is concomitant with patients who survive an initial acute injury, and these
patients remain at high risk for poor outcomes and long-term mortality, as well as a
significant financial burden [29]. Chronic kidney disease (CKD) and end-stage renal
disease (ESRD) are more likely to occur in patients who have had AKI in the past; in
fact, AKI is an independent risk factor for CKD and ESRD leading to increased
mortality and poorer outcomes [30-32]. An estimated 34 million people are
hospitalized per year, with an estimated financial burden of around 10 billion dollars
in healthcare costs associated with the hospital stays within the United States [28].
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Figure 1.5: Pooled incidence rate of AKI by world zones. Studies used Kidney
Disease Improving Global Outcomes (KDIGO) equivalent AKI definition.
Adapted from [2]

18

Types of AKI
AKI can be classified into three distinct categories based on the origin of the injury
causing the AKI. The three categories are 1) prerenal, 2) renal or intrinsic, 3)
postrenal. AKI incidents due to prerenal alterations in blood volume or a reduction in
blood flow into the kidney are estimated at around 70% for community-acquired AKI
and 40% for hospital-acquired AKI [33, 34]. Some prerenal AKI causes are cardiac
surgery, septic shock, blood loss (ex. hemorrhaging), and vascular disease, which all
ultimately decreases the amount of blood reaching the kidney causing ischemic
conditions and injury and organ dysfunction. As mentioned previously, the renal
epithelial cells of the proximal tubule mainly utilize oxidative phosphorylation to meet
their energy demands of various transport processes [7]. With an ischemic injury, the
oxygen levels plummet, significantly affecting the proximal tubules cells. Intrinsic
renal injury is when the injury originates inside the kidney, usually within the nephron
[35]. Medications, drugs, toxins, and ischemia are causes of intrinsic renal injury.
Postrenal AKI is an injury originating in the urinary tract but not inside the kidney,
commonly caused by an obstruction in the bladder or urethra [35]. This obstruction
causes pressure build-up and hydronephrosis [35].
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Causes of AKI
AKI can be caused by various etiologies including septic shock, cardiac surgery or
other major types of surgery, blood loss, vascular disease, urinary obstruction, and
drug/toxicant exposure. In the critically ill and hospitalized patient, sepsis is the major
cause of AKI and is responsible for nearly 50% of AKI cases [36]. Interestingly, the
medications that patients receive in the hospital can cause AKI, such as
aminoglycoside antibiotics, a plethora of chemotherapeutic agents, radiocontrast
media, and certain pain medication (non-steroidal anti-inflammatory drugs-NSAIDs).
Aminoglycosides, in particular, will accumulate in the proximal tubules cells of the
kidney and cause phospholipid metabolism alterations leading to nephrotoxicity and
decreased kidney function [37]. Aminoglycosides are very important life-saving
antibiotics; however, their toxicity to the kidney can compound renal dysfunction,
especially in ICU settings [38]. In a study following 61 patients in the ICU, 11.5% of
patients developed aminoglycoside-associated nephrotoxicity [39]. One of the more
well-known and studied chemotherapeutic agents, cisplatin, is associated with renal
toxicity. Recent evidence suggests that a metabolite of cisplatin preferentially
accumulates in the mitochondria and severely damages mitochondrial DNA [40, 41].
The renal proximal tubules have the highest density of mitochondria found in the
kidney, which leads to cisplatin metabolite accumulation and mitochondrial DNA
damage, and depletion of mitochondrial-encoded proteins [42]. Another common renal
tubule agent is radiocontrast media [43]. Various imaging machines and techniques
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need the patient to ingest or inject the media. This agent mainly affects patient
population with preexisting renal impairment associated diseases; however, this
population is also associated with needing radiocontrast media, causing increased AKI
incidence [44, 45]. NSAIDs are a common over the counter pain medication that has
been demonstrated to cause AKI, particularly in the elderly and people with poor renal
function before starting on NSAIDs [46]. NSAIDs cause damage by reducing blood
flow into the kidney by inhibiting prostaglandin production, and therefore affecting
vasodilation and vasoconstriction of the renal vessels. NSAID use is also associated
with acute interstitial nephritis (AIN), where inflammatory cells infiltrate the kidney
and cause inflammatory related renal damage [46, 47].
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Pathogenesis of Ischemia-Reperfusion Induced AKI
As mentioned previously, ischemia-reperfusion (IR) is a common AKI etiology.
Certain drugs and toxicants, major surgery (cardiac surgery), as well as certain
disease states including sepsis and vascular diseases are associated with reducing or
stopping blood flow to the kidney causing ischemic damage [48-50]. The lack of
oxygen and nutrients damages multiple cell types within the kidney and causes an
inflammatory response. The epithelial, endothelial, and inflammatory cells respond to
this ischemic environment and contribute to the AKI, [51]. Below is a chart outlining
IR-induced AKI pathogenesis (Figure 1.6).
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Figure 1.6: Pathogenesis of ischemic AKI. The major pathways of GFR
impairment in ischemic acute tubular injury are caused by ATP depletion in vascular
and tubular cells. Numerous interactions exist between endothelial cells, WBCs, and
epithelial cells in the pathophysiology of ischemic AKI. These interactions are
bidirectional between the cells involved, and result in specific functional and
structural alterations. Inflammatory mediators released from proximal tubular cells
influence endothelial cell processes (e.g. increase vasoconstriction and expression
of cell adhesion molecules) that in turn influence the interactions between WBCs
and endothelial cells, leading to reduced microvascular flow and continued hypoxia
within the local environment. Additional functional changes occur, such as a
marked reduction in production of erythropoietin and 25-hydroxylation of vitamin
D. Electrolyte accumulation can rapidly lead to requirement of renal replacement
therapy. Metabolic acidosis as a consequence of AKI must also be carefully
monitored. Abbreviations: AKI, acute kidney injury; FENa, fractional excretion of
sodium; GFR, glomerular filtration rate; TGF-β, transforming growth factor β;
WBC, white blood cell [24].
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The endothelial cells play a big role in renal damage due to IR injury. Endothelial cells
are responsible for maintaining vascular permeability, proper blood flow, regulating
vascular tone, as well as proper smooth muscle function [52, 53]. Even following IRinjury, the kidney continues to receive poor blood flow due to the damaged
endothelium. Vasoconstriction is left unchecked due to increased cytokine production
and release from endothelial-adhered leukocytes, such as IL-1β, TNF-α, and ET-1, and
decreased nitric oxide production following IR-injury [52, 54-56]. Other inflammatory
cells are easily passed through the damaged vasculature including neutrophils,
lymphocytes, and macrophages. These inflammatory cells will release inflammatory
mediators that can cause vasoconstriction, further restricting proper blood flow [57,
58]. Endothelial mitochondrial damage plays a role in endothelial-associated decreases
in microvasculature density, and by protecting the mitochondria, the microvasculature
becomes less injured [59, 60].

Renal epithelial cells, particularly the renal proximal tubule epithelial cells (RPTC),
are very sensitive to IR AKI. RPTC absorb and secrete many different substances and
these processes consume high levels of ATP, and therefore RPTC rely on oxidative
phosphorylation for their energy production. ATP depletion is a common occurrence
after IR injury and causes dysfunctional cellular process, and ultimately cell death [61,
62]. Loss of polarity, sodium-potassium ATPase transport activity, cytoskeletal
alterations, and mitochondrial dysfunction are other key RPTC processes that become

24

dysfunctional after IR injury leading to poor renal outcomes [7, 63, 64]. Apoptotic and
necrotic cell death are both observed following IR injury due to the aforementioned
altered processes [61, 62]. Severely damaged RPTC will have disruptions in their
adhesion complexes, making the RPTC unstable. If enough adhesion proteins are
disrupted, the tubule epithelial cells will detach from the basolateral membrane and
can form tubular casts in the tubular lumen, potentiating renal damage [7, 65]. New
cells will migrate and take up the space where the previous RPTC was and replace the
old dead epithelial cell. The exact source of these cells range from bone marrow
stromal cells, renal specific stem cells, and surviving renal epithelial cells
dedifferentiating [66-68]. Most recent evidence suggests that RPTC that become
damaged but do not undergo necrosis or initiate apoptosis, may actually
dedifferentiate, and migrate along the basement membrane and redifferentiate to
restore lost epithelial cells [65, 69]. The differentiated epithelial cells will undergo
gene and protein expression changes to express stem cell-related markers that help in
the repair processes, and become a renal-specific cell that resembles a typical stem
cell, [70-72]. Below is a diagram of normal repair in ischemic AKI, and two different
possible routes of restoring lost tubular cells after injury (Figure 1.7 and Figure 1.8).
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Figure 1.7: Normal Repair in Ischemic AKI. Following ischemic renal injury,
renal epithelial cells lose their polarity and brush border with proteins translocated
from the basolateral membrane to the apical membrane. In the case of severe
ischemia, cell death occurs via necrosis and/or apoptosis. Necrotic debris and
detached viable cells are released into the lumen, potentiating renal dysfunction.
Viable cells undergo division to replace lost cells, and subsequent differentiation
to restore nephron structure and function. Adapted from [7]
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As mentioned previously, mitochondria play a substantial role in providing the ATP
requirements for the various transport processes required to filter blood constantly in
the renal proximal tubules. As the main organelle in the RPTC for energy production,
any dysfunction to the mitochondria will have detrimental effects on the RPTC and
impair the transport processes, leading to improper absorption and secretion [73-75].
Studies have demonstrated that mitochondria become damaged after IR injury before
cellular injury and morphological changes can be observed, especially in the RPTC
[76]. Likewise, recent research has strongly suggested that preventing mitochondrial
damage from occurring after an insult and/or promoting repair of damaged
mitochondria can prevent maximal injury resulting from the insult and increase the
rate of renal recovery [75, 77].
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Ischemia-Reperfusion Model of AKI
Rodents, particularly rats and mice, are commonly used for renal IR experiments to
mimic human AKI. After a surgical midline excision, through both skin and muscle
layers, while the animal is under anesthesia, the renal artery or pedicle is located. The
renal artery is clamped either bilateral or unilateral for a specific amount of time,
depending on the specific model of AKI. After ischemia, the clamps are removed and
blood flow is observed to reperfuse the kidney, as a color change will occur (Figure
1.9). Experimental ischemia times can vary from one experimental study to the next
while achieving the same final outcome changes (ex. BUN, SCr). This most likely
stems from different core rodent body temperature maintained during surgery. Without
maintaining a specific core body temperature, clamping/ischemia times must be
greater than rodents with a maintained core body temperature [78-80]. In general, rats
are less sensitive to IR injury and require longer ischemia times than mice, as bilateral
clamping of rat renal pedicles typically needs 60 minutes to achieve the injury level of
18-30 minutes of clamping in mice [79]. Cell death, altered renal tubule blood flow,
loss of RPTC adhesion and cellular integrity, and lumen cast formation are all
observed, resulting from IR injury [81, 82].
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Figure 1.9: Representative images demonstrating induction of renal
ischemia following by reperfusion. Adapted from [4].
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Biomarkers of AKI
Novel AKI biomarkers have been researched heavily over the past decade. The earlier
renal injury can be detected the earlier potential treatment options may be initiated for
the patient, leading to better renal functional outcomes. Both urine and serum
biomarkers could be easily tested in a hospital setting. Serum creatinine (SCr) and
blood urea nitrogen (BUN) are two of the oldest and most common measurements for
renal dysfunction in both a clinical and research setting [83]. However, both SCr and
BUN have downfalls as a biomarker. The first is that increases in SCr and BUN may
not be observed until days after an injury has occurred, yet, GFR is well-below normal
[84]. This, in turn, could lead to an underestimated degree of injury, delayed
treatment, and a failure to discontinue renal toxic medications. Second, SCr and BUN
measurements can be altered by muscle mass, age, nutrition status, and medications
[85]. An ideal biomarker would not change due to the above non-injury related factors.
With the above limitations, there are now a multitude of new renal biomarkers being
studied, with greater sensitivity and fewer alterations due to non-injury related
changes in the patient. These biomarkers are being further studied to determine their
practical use in a hospital setting [86] (Figure 1.10). The below paragraphs will focus
on two specific biomarkers of kidney injury, neutrophil gelatinase-associated lipocalin
(NGAL) and kidney injury molecule-1 (KIM-1), as these are two molecules we
focused on in our research projects.
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NGAL, also known as lipocalin-2, was originally found in neutrophils and has a
molecular weight of 25-kDa [87]. NGAL is found in various epithelial cells within the
kidney, trachea, lungs, stomach, and colon, and its function is to scavenge labile iron
[88]. Labile iron is released from cellular organelles during an ischemic or septic
injury, and can further cause oxidative stress after the ischemic injury has abated [89].
NGAL is highly upregulated following renal ischemia, and was found expressed in
renal tubular cells in a mouse model of IR AKI [90, 91]. One of the first studies
demonstrating the favorable biomarker profile of NGAL over SCr, was performed in
2005, where in pediatric patients who had subclinical AKI expressed high NGAL
levels before SCr increased by 1-3 days [16]. An interesting finding was NGAL could
be tested for in the blood and/or urine [16]. Renal ischemia studies have revealed
NGAL expression levels increase in proportion to renal injury severity and duration,
with NGAL levels increasing as early as 1 hr after IR injury and up to 3 days before
any clinically relevant SCr changes [90, 92-94]. A potential limitation of NGAL as a
clinically relevant biomarker of AKI, is if the patient has a bacterial infection or
sepsis. Because neutrophils release NGAL after activation during a bacterial systemic
infection, the NGAL assay measurements become difficult to interrupt and distinguish
between infection and AKI [95, 96]. However, Canada and Europe has approved
NGAL for clinical use for patients with suspected AKI [92, 97, 98].
KIM-1 is a conserved type-1 transmembrane glycoprotein that contains an
immunoglobulin-like and glycosylated mucin domain [99]. KIM-1 protein is localized
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to the renal proximal tubular cells, and is expressed at very low levels under noninjured conditions [99]. However, following an ischemic or septic injury KIM-1
expression rapidly increases significantly [100]. Unique to KIM-1, as a biomarker, is
the specificity of demonstrating proximal tubule injury during AKI [99]. Following
renal injury, the ectodomain of KIM-1 is cleaved and shed into the tubular filtrate
within the lumen where it is excreted with the urine. Urine immunoassays were
developed to test for KIM-1 ectodomain in high-risk patients for AKI, such as
following cardiopulmonary bypass, cardiac catheterization, and ICU emergency
surgery [101, 102]. KIM-1 recognizes phosphatidylserine and oxidized lipoprotein
epitopes on the surface of apoptotic bodies that are found in the lumen following renal
injury. Once recognized, KIM-1 helps clear the lumen debris by facilitating
phagocytosis, which decreases an inflammatory response and helps prevent
obstruction within the tubule [103, 104]. KIM-1 mRNA increases within 3 hr
following renal IR injury and increased protein expression can be observed before
changes in SCr and BUN [105, 106]. Because KIM-1 is found in the proximal tubules,
the sensitivity for specifically denoting renal injury is higher than other biomarkers for
AKI (Figure 1.10) [105]. However, a limitation of KIM-1 is that the receptor helps
with repair processes, therefore finding increased KIM-1 in the urine may not help in
identifying early AKI as the KIM-1 in the urine may be present due to the recovery
phase. Recently, 32 urine biomarkers were studied following cardiac surgery for their
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predictive value in determining AKI severity; the combination of IL-18 and KIM-1
had the best predictability towards severe AKI [107, 108].
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Figure 1.10: Biomarkers of AKI. Traditionally used markers, such as blood urea
nitrogen (BUN) and creatinine (CR), are insensitive, nonspecific, and do not
adequately differentiate between the different stages of AKI. A delay in diagnosis
prevents timely patient management decisions, including administration of
putative therapeutic agents. Urinary biomarkers of AKI will facilitate earlier
diagnosis and specific preventative and therapeutic strategies, ultimately resulting
in fewer complications and improved outcomes [3]
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Pharmacological Treatment of AKI
Currently, there is no effective pharmacological treatment for AKI. Therapeutic
strategies for managing AKI involve maintaining proper fluid volume status,
controlling disease states associated with renal damage, discontinuing renal toxic
medications, and renal replacement therapy. Pharmacological agents have been
studied in the literature and include vasoactive drugs (dopamine, fenoldopam,
theophylline), anti-inflammatory drugs (aspirin, dexamethasone), and antioxidants (Nacetylcysteine) [109-114]. Figure 1.11 shows recent novel therapeutic agents for the
treatment of AKI (Figure 1.11) [115]. Developing a treatment option for AKI is
difficult as there are multiple pathophysiological mechanism of injury occurring in
parallel and in sequence [115]. Oxidative stress, disrupted cellular metabolism,
mitochondrial bioenergetics dysfunction, inflammation, apoptosis, and necrosis occur
simultaneously at the initiation of the injury and progression to AKI [116]. Because of
the aforementioned multitude of altered cellular and mitochondrial process, future
pharmacological drug trials will conceivably focus on a multi-targeted approach
possibly with more than one active drug being tested. The logic behind this approach
is to restore multiple known dysfunctional pathways after AKI, as single agent
approaches have not succeeded.
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Figure 1.11: Novel therapeutic agents for acute kidney injury.
Adapted from [112]
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MITOCHONDRIAL BIOLOGY
Mitochondrial Function
Mitochondria are subcellular organelles that generate the energy-rich molecule, ATP,
through oxidative phosphorylation, which regulates cellular metabolism and
homeostasis. Beyond ATP production, mitochondria are involved in a host of other
pathways, including, calcium storage and signaling, fatty acid oxidation, ROS
generation and signaling, citric acid cycle, regulating programmed cell death, initial
steroid hormone synthesis, heme synthesis, and heat production.

Mitochondrial Structure
The mitochondria is a membrane-bound organelle consisting of two membrane layers
made up of phospholipid bilayers, the outer mitochondrial membrane (OMM) and the
inner mitochondrial membrane (IMM). The OMM is a selectively permeable
membrane containing porins, channel proteins, for transporting various essential
molecules into the mitochondria. Because the IMM is much larger than the OMM, the
IMM is able to fit inside the OMM because it contains membrane folds called cristae,
and is a much more selective membrane barrier than the OMM [117]. The nature of
the mitochondrial structure consisting of the OMM and IMM helps form four different
areas within the mitochondria. The first consists of the OMM and the transport
channel proteins and some metabolic enzymes. The second, is the intermembrane
space, the space between the OMM and IMM, which maintains a proton gradient for
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the proper function of the electron transport chain (ETC). The third is the IMM, where
the ETC components are located, including, Complex 1-IV and ATP synthase. The
fourth is the mitochondrial matrix where many metabolic pathways occur, including
the citric acid cycle and fatty acid oxidation. The mitochondrial matrix contains the
mitochondrial DNA (mtDNA), which is circular double stranded DNA located in the
mitochondria and separate from the nuclear DNA. The mitochondrial matrix also
contains the enzymes and ribosomes for mtDNA transcription and mitochondrialencoded protein translation [117, 118].

Mitochondrial DNA
The mitochondria contain the only other source of DNA within the cell besides the
eukaryotic nucleus. mtDNA are maternally inherited DNA that are packaged inside
the inner mitochondrial membrane, usually along the cristae, in nucleoids [119, 120].
These nucleoids consist of mtDNA and specific mtDNA proteins required for stability,
replication, transcription, repair, and packaging [121]. mtDNA is circular double
stranded DNA containing 37 genes that encodes 13 subunits of the mitochondrial
oxidative phosphorylation system, 22 tRNAs, and 2 rRNAs. The other ~1500
mitochondrial proteins are transcribed from nuclear DNA [122]. The exact number of
mtDNA molecules per cell varies wildly from hundreds to thousands based on tissue
specific needs [123]. The kidney is the second highest mitochondrially dense organ
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behind the heart, although the mitochondria within the proximal convoluted tubules
are denser than the heart [124].
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Mitochondrial Homeostasis
Because the mitochondria play such a critical role in most cells life cycle, the proper
functioning of the mitochondria is essential for a healthy cell. Mitochondrial
homeostasis is the termed used for quality control over generating new mitochondria
(mitochondrial biogenesis) or programmed removal of damaged mitochondria
(mitophagy), as well as mitochondrial dynamics (fission and fusion) [125, 126].
Mitochondrial dynamics alters the morphology and consists of the interplay between
two distinctly different process, fission and fusion. Mitochondrial fission is the
process of dividing mitochondria into smaller mitochondrion. Fission requires the
cytosolic GTPase dynamin-related protein 1 (Drp1) and OMM located mitochondrial
fission 1 protein (Fis1). Mitochondrial fusion is the joining of separate mitochondria
to form branched and elongated mitochondrial networks. Fusion requires the OMM
located mitofusins 1 and 2 (Mfn1 and Mfn2) and the IMM located optic atrophy 1
(OPA1). Fusion and fission occur constantly throughout the cells life cycle and this
interplay can determine the energy status of the cell [127, 128]. Mitochondrial
mitophagy is the way in which the cell is able to degrade damaged or dysfunctional
mitochondrial by way of lysosomal digestion. Mitophagy is regulated through the
OMM located PTEN-induced putative kinase 1 (PINK1) and the cytosolic E3
ubiquitin ligase Parkin [129]. Figure 1.12 depicts the mitochondrial life cycle. (Figure
1.12 [8]
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Figure 1.12: Mitochondrial Life Cycle. Mitochondrial homeostasis is a
multifactorial process governed by MB, fission/fusion and mitophagy. PGC-1α
activates nuclear respiratory factor 1 (Nrf1) and nuclear respiratory factor 2 (Nrf2)
to coordinate the expression of nuclear genes required for MB. PGC-1α also
activate mitochondrial transcription factor A (TFAM) and mitochondrial
transcription factor B (TFBM), which regulate the transcription of genes encoded
by mtDNA. Mitochondria undergo cycles of fusion, which is mediated by
mitofusin (Mfn) 1, Mfn2 and optic atrophy protein (Opa1). Fission is mediated by
dynamin-related protein 1 (Drp1) and fission 1 (Fis1). Fission also promotes the
isolation of damaged mitochondria for selective mitochondrial degradation, a
process called mitophagy. Mitophagy involves the mitochondrial depolarization,
accumulation of putative kinase protein kinase 1 (Pink1) on the mitochondrial
membrane, recruitment of Parkin, which targets the mitochondria to the
autophagosome through the ubiquitination of mitochondrial proteins. Assembly of
the phagosome involves beclin-1, p62 and conjugation of microtubule-associated
protein 1 light chain 3 (LC3II). Adapted from [8].
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Mitochondrial Biogenesis
Mitochondrial biogenesis (MB) is broadly defined as the cell’s pathway to generate
new functioning mitochondria. MB can increase preexisting mitochondrial mass and
copy number and therefore, has the potential to increase energy production by way of
ATP synthesis. MB occurs under physiological conditions, but can be highly induced
due to various extracellular stressors, exercise, calorie insufficiency, and low body
temperatures [130, 131]. The master regulator of MB is the nuclear transcriptional
coactivator peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1α).
The PGC-1 family of transcriptional co-activators also includes PGC-1β and PGC-1related coactivator (PRC) that can also regulate MB. However, PGC-1α has been
shown to be abundantly expressed in tissues with high-energy demands, such as the
heart, skeletal muscle and the kidney. Increased PGC-1α or increased activity of PGC1α increases MB specific nuclear- and mitochondrial-encoded proteins required for the
generation of new mitochondria or increased mitochondrial mass [132, 133]. PGC-1α
enhances the following transcription factors, PPARs (PPARα, PPARδ, PPARγ),
estrogen related receptors (ERRα, ERRβ, and ERRγ), nuclear respiratory factors
(NRF-1 and NRF-2), and FOXO3 (forkhead box protein O3) [134, 135]. PGC-1α, like
its other PGC-1 family, contains an N-terminal activation domain consisting of
leucine-rich LXXLL motif that mediates its activity with other nuclear transcription
factors. As PGC-1α is a co-activator, it does not bind DNA but enhances the activity
of other transcriptional factor and their associated-protein binding complexes.
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NRF Transcriptional Regulation of Mitochondrial Biogenesis
NRF-1 and NRF-2 are nuclear transcription factors that upregulate specific nuclearencoded mitochondrial genes, and are enhanced by PGC-1α. NRF-1 increases the
expression of various mitochondrial-related genes, including mitochondrial ETC
complex components (ETC complex subunits, cytochrome C), mtDNA transcription
and translation (transcription factor A, TFAM), and mitochondrial protein transport
and assembly (TOM20, COX17) [136, 137]. NRF-2 is also a transcriptional factor for
other mitochondrial related targets, including mitochondrial respiration (subunit IV of
cytochrome c oxidase), mitochondrial import proteins (Tom20, Tom70), and mtDNA
transcription (TFAM) [136]. The importance of properly functioning mitochondrial
regulation can be found in NRF-1 and NRF-2 knockout mice, as mice with both NRFs
knocked out are lethal [138, 139].
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Mitochondrial Biogenesis in Renal Injury
As mentioned previously, the renal proximal tubule epithelial cells require lots of
oxygen to power oxidative phosphorylation, which supplies their high energy
requirements for the various transport processes that are constantly active for filtering
the blood. The mitochondrial density within RPTC is one of the highest of any organ
cell type in the body; hence, any injury that causes mitochondria dysfunction will
cause detrimental affects to the RPTC and ultimately kidney dysfunction. Acute
oxidant injury has been shown to cause mitochondrial dysfunction in RPTC, by
decreasing ATP levels and oxygen consumption rate in the mitochondria [140, 141].
Interestingly, overexpression of PGC-1α after oxidant injury in RPTC increased
mitochondrial specific proteins, ATP levels, and mitochondrial oxygen consumption
(Figure 1.13) [6]. In two experimental models of AKI, IR- and sepsis-induced, PGC1α mRNA is rapidly downregulated within 3 hr of initiated injury. This rapid
regulation of mitochondrial biogenesis after AKI, demonstrates the potential to target
PGC-1α and MB as a target of pharmacological treatment [142, 143].
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Figure 1.13: Overexpression of PGC-1α after oxidant injury restored
mitochondrial protein expression (A) as well as total cellular ATP (B) and
basal (C) and uncoupled (C) oxygen consumption in RPTC exposed to
tertbutyl-hydroperoxide [6]. Different superscripts indicate statistically
significant differences.
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Pharmacological Activation of Mitochondrial Biogenesis
Because the mitochondria play such a big role in RPTC physiology and
pathophysiology as mentioned above, the identification of a pharmacological agent
that would activate MB would be a great therapeutic strategy for prevention of RPTC
injury or increasing repair following AKI. For this reason, pharmacological agents that
control PGC-1α have been a central focus in our lab, as well as many others. Using
pharmacological agents to modulate upstream MB pathways such as AMP kinase,
sirtuins, cyclic AMP and GMP, B2 receptor, and the 5-HT1F receptor has shown
promise in activating MB [144-151]. Figure 1.14 showcases the multitude of pathways
that regulate MB, mostly through the co-activator PGC-1α [152].
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Figure 1.14: Pharmacological Activation of MB. MB is a complex process
controlled by the transcriptional regulator, PGC-1α. PGC-1α expression and
activity is regulated by a variety of pathways including receptor tyrosine kinases,
G-protein coupled receptors (GPCR), naturetic peptide receptors, cyclic
guanosine monophosphate (cGMP), ERK1/2, as well as SIRT1-mediated
deacetylation.
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Likewise, targeting negative regulators of MB would be of therapeutic benefit. Instead
of increasing an activation pathway (as discussed above), an inhibition or blockade of
physiological or pathological signaling that negatively regulates PGC-1α or other MB
pathways would conceivably be of benefit before, during, or after AKI has occurred.
Negative regulation of MB has been observed in multiple forms of AKI, including IR
injury, sepsis, gentamycin toxicity, and folic acid nephropathy, where mitochondrial
gene targets and proteins are downregulated rapidly after injury [126, 142, 143, 153156]. Negative regulation of MB does not only occur in injured states, but has also
been observed to occur in an age-associated manner [157, 158]. Multiple negative
regulator pathways have been studied including the transcription factors, receptorinteracting protein 140 (RIP140), hypoxia-inducible factor 1-α (HIF-1α), and
mitochondrial transcription termination factor 3 (MTERF3) [132]. The proinflammatory cytokine tumor necrosis factor alpha (TNF-α) has been demonstrated to
downregulate MB through an eNOS dependent manner and cause mitochondrial
dysfunction by decreasing mitochondrial proximity with sarcoplasmic reticulum. [159161]. The mitogen-activated protein kinase (MAPK), ERK1/2 (extracellular signalregulated kinases 1/2), when activated, has been shown to reduce mitochondrial basal
respiration and ATP production, reduce uncoupled oxygen consumption, disrupt
mitochondrial membrane potential, initiate iron-induced mitochondrial swelling, and
decrease MB targets [142, 162-167]. The remainder of the dissertation will focus on
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ERK1/2 signaling and inhibition of ERK1/2 activation following multiple models of
AKI in mice, with a key focus on MB and disruption of mitochondrial homeostasis.
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Intracellular Signaling
Intracellular signaling is an important and complex cellular pathway by which all
different cell types respond to extracellular stimuli and events. The purpose of
intracellular signaling is to allow the cell to respond and adjust to environmental
factors and extracellular stimuli presented to the cellular surface. In this way the cell
can upregulate or downregulate certain signaling pathways that would potentially be
more beneficial for the cell in their current environment. These intracellular signaling
events can occur rapidly, which allows the cell to respond in a timely manner to adapt
and thrive. Examples of changes within the cell that could occur are alterations in gene
transcription, protein expression, post-translational modifications, protein
translocation, enzyme activity rates, and changes in cellular metabolism [168, 169].

Extracellular stimuli and/or environmental factors have the ability to stimulate various
receptors on the cell surface causing activation of the receptors through ligand binding
and/or non-binding (temperature) of the receptor. These receptors could be ion
channel-linked (ex. 5-HT receptor), enzyme-linked (ex. receptor tyrosine kinase), and
G-protein-coupled (ex. β2-adrenergic receptor). Once activated the receptors stimulate
intracellular targets by way of recruitment and adapter proteins that are usually located
near the cell surface from the cytosolic side along the membrane [170, 171].
Depending on the receptor type and activation, the adaptor proteins stimulate a
signaling cascade where one activation leads to another activation in a stepwise
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manner. One of the most well-known and studied intracellular signaling cascade is the
mitogen-activated protein (MAP) kinase pathway. The classical MAP kinases are Jun
N-terminal kinase (JNK), p38, and ERK. The ERK family is one of the bestcharacterized family of MAP kinases, specifically ERK1 and ERK2 [172].

Extracellular Signal-Regulated Kinase 1/2
ERK1/2 was found to become highly phosphorylated by addition of epidermal growth
factor (EGF) and platelet-derived growth factor (PDGF) to developing chicken
embryos [173]. At the time (1983), the authors did not know they were studying
ERK1/2 just proteins of 40 and 42 kDa [173]. ERK1/2 becomes phosphorylated
through growth factor stimulation because once bound to the receptor, a signaling
cascade begins and preceding in a step-wise manner until phosphorylation of ERK1/2.
Stimulation of receptor tyrosine kinases (RTKs) causes dimerization of the receptor,
and allows autophosphorylation to occur [174]. The adapter protein growth factor
receptor-bound protein 2 (Grb2) can now bind to the intracellular phosphorylated
portion of the RTK, and recruits Son of Sevenless (Sos). This Grb2 and Sos complex
allows for inactive Ras GTPases to locate to the activated RTK [175]. The three
subfamily of Ras proteins that activate the ERK1/2 signaling cascade are H-Ras, KRas, and N-Ras. Inactive Ras is Ras bound with GDP. Upon association with Grb2
and Sos complex, Ras releases GDP and binds GTP, which promotes conformational
changes to Ras. These changes create a better surface for protein-protein interactions,
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which leads to activation of various effector proteins (Raf, phospholipase C) from the
cell surface and downstream signaling throughout the cytosol, mitochondria, and
nucleus [172].

The main effector, with respect to ERK1/2 signaling, is the Raf family of kinases.
There is A-Raf, B-Raf, and C-Raf, which are serine/threonine kinases. Once Ras has
become activated, Rafs phosphorylate and activate MEK1 and MEK2 (MEK1/2) [176,
177]. Raf kinase localization and activity are dependent on the multiple
conformational changes and phosphorylations they can undergo [177, 178]. For C-Raf,
phosphorylation at Ser338 and Tyr341 are needed for Raf kinase activity. B-Raf has a
higher basal kinase activity than C-Raf because B-Raf contains a phosphomimetic at
position 448, which mimics C-Raf phosphorylation at Tyr341. Raf kinases (and other
MAP kinase kinases) phosphorylate MEK1 and MEK2 on Ser218 and Ser222, and
both amino acids becoming phosphorylated are required for full activation [172, 179].
MEK1/2, once activated, can phosphorylate ERK1 and ERK2, which are the only
known substrates of MEK1/2. Figure 1.15 shows the ERK1/2 signaling cascade [5].
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Figure 1.15: Schematic Representation of the Ras-Raf-MEK-ERK1/2
MAP kinase pathway. GF, growth factor; RTK, receptor tyrosine kinase.
Adapted from [5].
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ERK1 is phosphorylated at Thr202 and Tyr204 and ERK2 is phosphorylated at
Thr183 and Tyr185, and both phosphorylation sites are required for maximal activity
of ERK1/2 [180, 181]. ERK1 and ERK2 contain ~85% sequence identity, 100%
similar catalysis and docking residues, are activated from identical stimuli, perform
similar downstream functions inside the cell, and are co-expressed in almost all cell
types [182-185]. However, ERK2 knockout mice are embryonic lethal, whereas ERK1
knockout mice are not and are fertile, pointing to ERK2 playing a more essential role
in mouse embryo development [186-188]. Contradicting this ERK specific
developmental assumption, is a study by Fremin et al., which demonstrated mice
embryos developed normally in ERK2 deficient embryos by increasing ERK1 by an
Erk1 transgene [189]. Therefore, ERK1 and ERK2 may be functionally repetitive
during mouse developmental stages as well as in a mature mouse, and any knockdown
of one kinase, ERK1 or ERK2, led to observable effects merely because of a decrease
in total kinase protein levels [184, 189, 190].

ERK1/2 can be anchored in the cytoplasm by various proteins, including MEKs and
MAP kinase phosphatase 3 (MKP-3). However, ERK1/2 can translocate into the
nucleus by way of passive diffusion, as the size of ERK1 (44 kDa) and ERK2 (42kDa) is small enough to not require ATP or specialized protein transporters [191, 192].
This translocation process is dynamic and ERK1/2 do not contain nuclear export
sequence, but rather ERK2 is exported by both energy- and carrier-independent
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mechanisms, mediated in part by the exportin, Exportin 1 (XPO1 or CRM1) and the
nuclear pore complex, specifically the nucleoporin, Tpr [193-196].
Extracellular stimuli can activate ERK1/2 in minutes which can be critical for the cell
(and tissue/organ) depending on the biological response required to initiate. ERK1/2
has been shown to be involved with cell survival, cell death, differentiation,
proliferation, migration, transcription, and translation among others [172, 197, 198].
To accomplish the above-mentioned biological responses, ERK1/2 phosphorylates
various cellular substrates, and these substrates perform downstream cellular functions
that ultimately provide the response for the specific stimulus. Currently, ERK1/2 was
found to have 659 direct phospho-site targets on various substrates [199]. Among
those substrate targets of ERK1/2 are upstream proteins involved in ERK1/2
activation, including Sos1, Raf, and MEK1. Interestingly, ERK1/2 phosphorylation of
these upstream proteins decreases its own activation signal, by diminishing each
substrates activity for continuing to stimulate the ERK1/2 signaling cascade [172, 200203].
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CHAPTER TWO:
Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor γ
Coactivator-1α by Extracellular Signal-Regulated Kinase 1/2 in Physiological and
Pathological Conditions
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ABSTRACT
Previous studies have shown that extracellular signal-regulated kinase 1/2 (ERK1/2)
directly inhibits mitochondrial function during cellular injury. We evaluated the role
of ERK1/2 on the expression of peroxisome proliferator-activated receptor γ
coactivator-1α (PGC-1α) gene, a master regulator of mitochondrial function. The
potent and specific MEK1/2 inhibitor trametinib rapidly blocked ERK1/2
phosphorylation, decreased cytosolic and nuclear FOXO3a/1 phosphorylation, and
increased PGC-1α gene expression and its downstream mitochondrial biogenesis
(MB) targets under physiological conditions in the kidney cortex and in primary renal
cell cultures. The epidermal growth factor receptor (EGFR) inhibitor erlotinib blocked
ERK1/2 phosphorylation and increased PGC-1α gene expression similar to treatment
with trametinib, linking EGFR activation and FOXO3a/1 inactivation to the downregulation of PGC-1α and MB through ERK1/2. Pretreatment with trametinib blocked
early ERK1/2 phosphorylation following ischemia/reperfusion kidney injury and
attenuated the down-regulation of PGC-1α and downstream target genes. These results
demonstrate that ERK1/2 rapidly regulates mitochondrial function through a novel
pathway, EGFR/ERK1/2/FOXO3a/1/PGC-1α, under physiological and pathological
conditions. As such, ERK1/2 down-regulates mitochondrial function directly by
phosphorylation of upstream regulators of PGC-1α and subsequently decreasing MB.
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Introduction
ERK1/2 is a major player in various cell signaling pathways, including proliferation,
differentiation, senescence, cell injury and recovery, and apoptosis. ERK1/2 becomes
activated through a variety of extracellular stimuli, including receptor tyrosine kinases
(RTK) such as the epidermal growth factor receptor (EGFR), which leads to the
activation of mitogen-activated protein kinase kinase (MEK) (1,2). EGFR agonists
activate intrinsic tyrosine kinase activity within the cytoplasmic domain of the receptor,
initiating the recruitment of Ras, a GTPase, which allows for interaction with
downstream effectors, including the Raf protein kinases. Raf phosphorylates MEK1/2,
which phosphorylates ERK1/2. ERK1/2 is thought to be the only substrate for MEK1/2
phosphorylation, which has allowed for MEK1/2 inhibitors to be used specifically for
ERK1/2 inactivation (3,4).
ERK1/2 is also activated by cell stressors, including reactive oxygen species (ROS).
Utilizing H 2 O 2 injury in human renal cells, ERK1/2 inhibition was shown to decrease
necrosis and apoptosis (5), while in a cisplatin-induced cell injury model ERK1/2
inhibition reduced caspase 3 activation and apoptosis (6). In renal proximal tubular cells
(RPTC), phosphorylated ERK1/2 was shown to reduce mitochondrial respiration and
ATP production by decreasing complex I electron transport chain activity in response to
tert-butyl hydroperoxide (TBHP), a model oxidant (7). Nowak, et al., also showed that
expression of a constitutively active MEK1 increased ERK1/2 activation and decreased
basal and uncoupled oxygen consumption, a measure of electron transport chain activity
(7). Zhuang, et al., demonstrated that H 2 O 2 treatment of RPTC led to a high level of
ERK1/2 phosphorylation and loss of mitochondrial membrane potential (MMP) which
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was attenuated by treating with a MEK/ERK1/2 inhibitor. Finally, Fe2+-induced
mitochondrial swelling was shown to occur through activation of the ERK1/2 pathway
(8). These findings illustrate that ERK1/2 decreases mitochondrial function in response
to injury.
The kidney is a high-energy consuming organ and its cells have an abundance of
mitochondria to meet ATP demand, especially within the proximal tubules (9). Previous
studies demonstrated that rapid and persistent disruption of mitochondria homeostasis is
an important contributor to the pathology of renal ischemia/reperfusion (IR) injury
(10,11). PGC-1α is thought to be the master regulator of mitochondria biogenesis (MB)
and is enriched in tissues with high metabolic demand, such as the heart, skeletal
muscle, and kidney (12,13). The role of ERK1/2 activation and subsequent regulation of
PGC-1α and downstream targets involved in mitochondrial homeostasis and
dysfunction remains limited.

Physiological and pathological stimuli, such as exercise, caloric restriction, hypoxia,
sepsis, and ischemia/reperfusion (IR) are known to alter PGC-1α expression (9,14). IRinduced renal injury rapidly suppresses MB, PGC-1α and its direct downstream targets
at the transcriptional and protein level (10,11,13). However, the mechanism(s) by which
PGC-1α is transcriptionally suppressed after injury has not been determined. Therefore,
we examined the role of ERK1/2 in renal PGC-1α transcription under physiological and
pathophysiological conditions in primary cultures of RPTC and in the renal cortex of
mice. We determined that ERK1/2 regulates PGC-1α in RPTC and in the renal cortex of
mice at a physiological level through phosphorylation of the transcription factors
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FOXO3a/1. EGFR was found to be the upstream activator of ERK1/2 under basal
conditions, negatively regulating PGC-1α transcription. Finally, under the
pathophysiological condition of IR-induced AKI in mice, ERK1/2 activation was
responsible for the initial decrease in PGC-1α mRNA expression and the decrease in
kidney function as measured by serum creatinine. By inhibiting ERK1/2 activation we
attenuated the early decrease in PGC-1α and prevented the decrease in kidney function.
This research is significant because PGC-1α is the key regulator for MB and by
sustaining mitochondrial homeostasis ERK1/2 inhibition may be a potential therapeutic
to prevent further injury and/or increase recovery where early mitochondrial
dysfunction is observed.
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RESULTS
ERK1/2 Inhibition Increases PGC-1α and MB Proteins mRNA in RPTC.
To test the hypothesis that ERK1/2 regulates PGC-1α and MB at a physiological level,
we utilized the pharmacological MEK1/2 inhibitor trametinib and primary cultures of
rabbit RPTC. Trametinib has been well-characterized as a potent and specific inhibitor
of MEK1/2 with an IC 50 of 0.92 to 3.4 nM in various cell lines and shows limited
inhibitory activity against at least 98 other kinases (15,16). RPTC were treated with 0.3,
1, or 10 nM trametinib, and at 10 nM ERK1/2 phosphorylation was completely
inhibited after 4 hr (Figure 2.1A). Trametinib (10 nM) completely inhibited ERK1/2
phosphorylation within 10 min and continued to inhibit for 24 hr (data not shown)
without altering total ERK1/2 (Figure 2.1A). PGC-1α mRNA expression increased 1.8fold at 1 hr and 2.8-fold at 4 hr before decreasing to control levels at 24 hr after
trametinib exposure (Figure 2.1B). The increase in PGC-1α mRNA was linked to
increased nuclear-encoded mediators of MB and gene targets of PGC-1α, including
mitochondrial transcription factor A (TFAM), nuclear respiratory factor-1 (NRF1), and
NADH Dehydrogenase (Ubiquinone) Fe-S Protein 1 (NDUFS1) at 1, 4 and 24 hr after
trametinib treatment (Figure 2.1C-E). These results reveal that ERK1/2 represses PGC1α mRNA expression and its downstream target genes under physiological conditions
and that inhibition of ERK1/2 activation results in a rapid induction of PGC-1α mRNA
and other downstream MB genes.
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Figure 2.1: ERK1/2 inhibition increases levels of PGC-1 and downstream
targets of MB mRNA. A, immunoblotting analysis of phosphorylated ERK1/2 (pERK1/2) in RPTC in response to increasing concentrations of trametinib at 4 h and
increasing time of exposure to 10 nM trametinib. Veh, vehicle; MW, molecular
weight. B–E, mRNA expression of PGC-1, TFAM, NDUFS1, and NRF1 at 1, 4, and
24 h after treatment with 10 nM trametinib. Data are represented as mean S.E., n >
5. Different superscripts indicate statistically significant differences (p < 0.05).
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ERK1/2 Regulates PGC-1α Through Phosphorylation of FOXO3a Independent of
p38 and AKT Kinases in RPTC.
We analyzed the phosphorylation levels of FOXO3a in RPTC 30 min after trametinib
treatment since FOXO3a is a direct transcriptional regulator of PGC-1α (17-19).
Phosphorylation of the ERK1/2 phosphorylation site, serine 294, on FOXO3a decreased
54% at 30 min in RPTC treated with trametinib (Figure 2.2A-B). Other kinases, such as
p38 and AKT are known to target FOXO3a for phosphorylation (20,21); however, p38
and AKT phosphorylation did not change in the presence of trametinib (Figure 2.2C).
To exert its transcriptional effects, FOXO3a shuttles between the cytosol and the
nucleus (22). Phosphorylation of FOXO3a inactivates the protein by preventing it from
entering the nucleus and increases the rate of export from the nucleus to the cytosol
where it may be degraded (23). Therefore, phosphorylation of FOXO3a decreases its
ability to bind to promoters and increase gene expression (20,23,24). Nuclear
phosphorylated FOXO3a decreased 60% in the trametinib-treated RPTC at 30 min with
no alteration in total FOXO3a nor the loading control, lamin B1 (Figure 2.2D-E). In
summary, phosphorylated ERK1/2, but not AKT or p38, phosphorylates FOXO3a,
which inactivates FOXO3a in the nucleus, and prevents FOXO3a from increasing PGC1α expression physiologically. This dynamic control of FOXO3a by ERK1/2 regulates
PGC-1α rapidly leading to a decrease/increase MB gene regulation.
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Figure 2.2: ERK1/2 regulates PGC-1 through phosphorylation of FOXO3a
independent of p38 and AKT kinases in RPTC. A, representative immunoblot of
pFOXO3a after 10 nM trametinib treatment in RPTC. p, phosphorylated; Veh, vehicle;
MW, molecular weight. B, densitometry analysis of phosphorylated FOXO3a, with actin as loading control. C, densitometry analysis of p38 and AKT kinases. D,
representative immunoblot of phosphorylated and total FOXO3a in the nucleus. E,
densitometry analysis of phosphorylated FOXO3a in the nucleus following ERK1/2
inhibition. Data are represented as mean S.E., n > 5. Different superscripts indicate
statistically significant differences (p < 0.05).
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EGFR Inhibition Increases PGC-1α mRNA Expression by Preventing ERK1/2
Activation in RPTC.
EGFR is known to regulate the activity of the ERK1/2 signaling cascade (1,25,26). To
determine whether ERK1/2 inhibition of PGC-1α mRNA was mediated by the EGFR in
RPTC, we utilized the EGFR inhibitor erlotinib, a direct inhibitor of the intracellular
kinase domain of the EGFR that prevents autophosphorylation and signal transduction
(26). Within 1 hr of erlotinib treatment (100 nM and 1 µM), ERK1/2 phosphorylation
was blocked without a change in total ERK1/2 protein and remained decreased 4 hr post
treatment (Figure 2.3A). PGC-1α mRNA expression was increased at 4 hr by 2.4- and
2.8-fold in the 100 nM and 1 µM erlotinib groups, respectively (Figure 2.3B). NRF1
was also up 2.4-fold by 4 hr after EGFR inhibition (Figure 2.3C). We conclude that
EGFR inhibition with erlotinib leads to an upregulation of PGC-1α mRNA through
inactivation of ERK1/2. It should be noted that the 4 hr increases in PGC-1α mRNA
expression are very similar to the increases observed using trametinib (Figure 2.1B). In
summary, under physiological conditions the activation of the EGFR/ERK1/2/FOXO3a
pathway regulates PGC-1α and MB genes within 1 hr.
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Figure 2.3: EGFR inhibition increases PGC-1 mRNA expression by preventing
ERK1/2 activation in RPTC. A, representative immunoblot of phosphorylated
ERK1/2 after treatment with increasing concentrations of erlotinib
(ErL) at 1 and 4 h in RPTC. p, phosphorylated; Veh, vehicle. B and C, mRNA
expression of PGC-1 (B) and NRF1 (C) following increasing concentrations of
erlotinib at 4 h. Data are represented as mean S.E., n > 5. Different superscripts
indicate statistically significant differences (p <0.05).
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ERK1/2 Physiologically Regulates PGC-1α Expression and Protein by Altering
FOXO1 Phosphorylation in the Mouse Kidney.
Our laboratory and others have previously reported that a 1 mg/kg dose of trametinib
inhibits ERK1/2 phosphorylation in mice (16,27). We verified that trametinib (1 mg/kg,
i.p.) inhibited ERK1/2 phosphorylation at 4 hr post-injection in the renal cortex with no
change to total ERK1/2 protein (Figure 2.4A). PGC-1α mRNA expression in the renal
cortex increased 1.5-fold 4 hr after ERK1/2 inhibition, corresponding with the
observations made in vitro (Figure 2.4B). Likewise, targets of PGC-1α were also
upregulated at 4 hr with NRF1 mRNA elevated by 1.8-fold and TFAM mRNA up 1.2fold (Figure 2.4C). Cytochrome c oxidase I (COX1) mRNA, a mitochondrial encoded
gene, one of the subunits of respiratory complex IV, was also upregulated 1.4-fold
following ERK1/2 inhibition with trametinib (Figure 2.4C). The increase in MB gene
expression due to ERK1/2 inhibition resulted in increases in PGC-1α and TFAM
proteins of 1.6-fold and 1.3-fold, respectively, at 4 hr in the trametinib group (Figure
2.4B, D-E).
After failing to detect FOXO3a in the mouse renal cortex (data not shown), we
examined FOXO1. FOXO3a and FOXO1 are similar transcription factors and share
overlapping activities, including regulating PGC-1α (20). FOXO1 phosphorylation at
the phosphorylation site, serine 329, was decreased in the trametinib group
(28,29)(Figure 2.5A-B). Total FOXO1 protein did not change in response to ERK1/2
inhibition (Figure 2.5A). Neither AKT and p38 phosphorylation nor total AKT and p38
proteins changed in the trametinib group (Figure 2.5C). Trametinib treatment decreased
nuclear phosphorylated FOXO1 to total FOXO1 32%, 4 hr after trametinib (Figure
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2.5D-E). FOXO1 mRNA was also upregulated at 4 hr post ERK1/2 inhibition (Figure
2.5F). Further evidence that ERK1/2 inhibition results in increased FOXO1 gene
transcription was revealed by increases in catalase and mitochondrial superoxide
dismutase 2 (SOD2), two genes regulated by FOXO1 (Figure 2.5F) (30,31). We
conclude that ERK1/2 regulates the activity of FOXO1 within the nucleus and controls
the basal level of PGC-1α mRNA and subsequent PGC-1α protein levels, as well as
downstream MB genes in the kidney.
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Figure 2.4: ERK1/2 physiologically regulates PGC-1 expression and protein in
mouse kidney. A, representative immunoblot of phosphorylated ERK1/2 after
treatment with trametinib in mouse kidney cortex. p, phosphorylated; MW,
molecular weight. B, representative immunoblot of PGC-1 and TFAM proteins after
treatment with trametinib in the kidney cortex. The black line represents the splicing
of the blot from the same membrane. C, mRNA expression of PGC-1, NRF1,
TFAM, and COX 1 following trametinib administration at 4 h. D and E,
densitometry analysis of PGC-1 (D) and TFAM (E) protein at 4 h following
trametinib. Data are represented as mean S.E., n > 5. Different superscripts indicate
statistically significant differences (p < 0.05).

82

Figure 2.5: FOXO1 phosphorylation in the cortex and nuclear phosphorylation
decrease after ERK1/2 inhibition. A, representative immunoblot of
phosphorylated FOXO1 and ERK1/2, AKT, and p38 kinases following trametinib
administration. p, phosphorylated; MW, molecular weight. B, densitometry analysis
of phosphorylated FOXO1 when compared with total FOXO1. C, densitometry
analysis of phosphorylated AKT to total AKT, and phosphorylated p38 to total p38
after trametinib treatment. D, representative immunoblot of nuclear phosphorylated
FOXO1 and ERK1/2 after trametinib treatment in mouse kidney cortex. E,
densitometry analysis of phosphorylated FOXO1 when compared with total FOXO1
after inhibition of ERK1/2 in the nucleus. F, mRNA expression of FOXO1, SOD2,
and catalase at 4 h following trametinib administration. Data are represented as
mean S.E., n > 4. Different superscripts indicate statistically significant differences
(p < 0.05).
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ERK1/2 Inhibition During AKI Attenuates an Increase in Serum Creatinine and
Decreases in PGC-1α and NRF1 Expression.
To examine the role of ERK1/2 on PGC-1α in the renal cortex under injurious
conditions, we pretreated mice with trametinib or vehicle for 1 hr and then subjected
mice to bilateral IR surgery or sham surgery for 18 min to induce AKI and kidneys were
collected 3 hr later. IR-induced AKI decreases PGC-1α mRNA expression, as well as
other mitochondrial genes and proteins (32). Trametinib prevented the increase in
ERK1/2 phosphorylation following the IR (Figure 2.6A). PGC-1α mRNA decreased
41% in IR mice after 3 hr and trametinib attenuated this decrease (Figure 2.6B).
Interestingly, trametinib pretreatment increased NRF1 expression following IR
compared to sham, whereas IR alone resulted in 13% decrease in NRF1 compared to
sham (Figure 2.6B). At the protein level both PGC-1α and TFAM proteins increased
1.7- and 2.4-fold, respectively (Figure 2.6C-D).
Serum creatinine, a marker of renal dysfunction increased 4-fold in the IR group at 3 hr
and was attenuated in the trametinib pretreatment group (Fig 6E). We demonstrate that
by inhibiting ERK1/2 phosphorylation prior to inducing IR AKI we attenuated the
decreases in PGC-1α and NRF1 mRNA, as well as increasing mitochondrial related
proteins PGC-1α and TFAM 3 hr post-surgery. By maintaining mitochondrial function
due to ERK1/2 inhibition kidney dysfunction was prevented at 3 hr.
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Figure 2.6: ERK1/2 inhibition during AKI attenuates an increase in serum
creatinine and increases PGC-1 and TFAM proteins. A, representative
immunoblot of phosphorylated ERK1/2, total ERK1/2, TFAM, and PGC-1
following IR AKI. p, phosphorylated; MW, molecular weight. B, mRNA expression
of PGC-1 and NRF1 following IR AKI at 3 h after IR in the kidney cortex. C and D,
densitometry analysis of PGC-1 (C) and TFAM (D) proteins following 3 h IR. E,
serum creatinine was assessed 3 h after IR AKI. Data are represented as mean S.E.,
n > 5. Different superscripts indicate statistically significant differences (p < 0.05).
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Erlotinib Blocks ERK1/2 Phosphorylation in Naïve Mice and Following IR,
Preventing Decreases in PGC-1α and NRF1 Expression.
To elucidate the role of EGFR on ERK1/2 and PGC-1α and MB genes in the renal
cortex, erlotinib (50 mg/kg i.p.) was administered to naïve mice (33). Erlotinib
decreased ERK1/2 phosphorylation by 45% in the kidney cortex 4 hr after
administration (Figure 2.7A-B). Mice given erlotinib had 1.3-fold higher PGC-1α
mRNA and 1.4-fold higher FOXO1 mRNA expression (Figure 2.7C). To elucidate if
the EGFR is the upstream receptor required for the ERK1/2 activation that
downregulates PGC-1α following IR AKI we pretreated with erlotinib prior to inducing
IR AKI. We observed attenuation in the increase of phosphorylated ERK1/2 at 3 hr
compared to IR alone (Figure 2.7D-E). Very similar to the results obtained in the
trametinib experiments (Figure 2.6B-C), we observed attenuation of PGC-1α and NRF1
mRNA compared to the IR group, as well as an increase in PGC-1α protein (Figure
2.7F-G). The erlotinib group also prevented the 5-fold increase in serum creatinine seen
in the IR group (Figure 2.7H). These data reveal that EGFR actively regulates ERK1/2
phosphorylation in the kidney, and as a consequence, EGFR regulates renal PGC-1α
mRNA at a physiological and pathophysiological level. In summary, EGFR is the
upstream receptor regulator of basal ERK1/2 phosphorylation in the renal cortex that
controls PGC-1α mRNA and MB genes.
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Figure 2.7: Erlotinib blocks ERK1/2 phosphorylation in naïve mice and
following IR, preventing decreases in PGC-1α and NRF1 expression. A,
representative immunoblot of phosphorylated ERK1/2 after 4 h of treatment with
erlotinib in mouse kidney cortex. p, phosphorylated; MW, molecular weight. B,
densitometry analysis of phosphorylated ERK1/2 when compared with total ERK1/2
following 4 h of erlotinib treatment. C, mRNA expression of PGC-1α and FOXO1
at 4 h in mouse cortex following erlotinib treatment. D, representative immunoblot
of phosphorylated ERK1/2 and total ERK1/2, as well as PGC-1α following IR AKI.
E, densitometry analysis of phosphorylated ERK1/2 when compared with total
ERK1/2 following 3 h of IR AKI. F, densitometry analysis of PGC-1α protein when
compared with β-actin following 3 h of IR AKI. G, mRNA expression of PGC-1α
and NRF1 following 3 h of IR AKI. H, serum creatinine was assessed 3 h after IR
AKI. Data are represented as mean S.E., n > 4. Different superscripts indicate
statistically significant differences (p < 0.05).
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DISCUSSION
In this study we identified ERK1/2 as an important and rapid regulator of PGC-1α gene
transcription in RPTC and in mouse kidney under physiological and pathological
conditions. In RPTC, we showed trametinib inhibits ERK1/2 phosphorylation within 10
min leading to an increase in PGC-1α mRNA expression which was sufficient to upregulate mitochondrial genes involved in MB. In addition, we determined that EGFR
was the upstream activator of ERK1/2 in both RPTC and renal cortex. Thus, the
EGFR/ERK1/2/FOXO(3a/1) pathway is an important negative regulator of PGC-1α and
its downstream targets, including MB genes.

Previous studies revealed that ERK1/2 down regulates mitochondrial function by
decreasing basal and uncoupled oxygen consumption following TBHP exposure in
RPTC (7). Furthermore, ATP production was reduced 40% in RPTC due to ERK1/2
activation by TBHP, and by inhibiting ERK1/2 ATP remained at control levels. In
contrast, ERK1/2 inhibition was found to decrease ATP production and cause a rapid
loss of mitochondrial membrane potential in alveolar macrophages (34), but not in
primary cultures of tracheobronchial epithelial cells or lung fibroblasts. A decrease in
oxygen consumption through inhibition of complex I in HL-60 cells was found to occur
by ERK1/2 inhibition (35). Overall, ERK1/2 decreases mitochondrial function by three
mechanisms: 1) post-translation modifications that decrease electron transport chain
activity, 2) down regulation of PGC-1α and mitochondrial gene expression, and 3)
decreased expression of mitochondrial protectants (i.e. SOD2). However, ERK1/2
appears to regulate mitochondrial functions differently in various cell types and the
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differences may be based on the level of oxidative phosphorylation that occurs in each
cell type. RPTC used by Nowak et al. and in our studies derive all their energy from
oxidative phosphorylation, similar to that found in kidney cortex.

In RPTC, FOXO3a phosphorylation was decreased 30 min post trametinib treatment.
These results are consistent with previous studies that show ERK1/2 regulates
phosphorylation of FOXO3a (23,36). Phosphorylation is a key determinant of FOXO3a
localization and its regulation of PGC-1α (37-39). Yang et al., showed that ERK1/2
phosphorylation of FOXO3a promotes a FOXO3a degradation pathway mediated by the
E3 ubiquitin ligase MDM2 (23). We show that ERK1/2 inhibition decreased
phosphorylated FOXO3a in the nucleus, allowing greater FOXO3a and PGC-1α
expression physiologically. This FOXO3a dependent increase in PGC-1α was also
shown during endothelial oxidative stress (19).

It is not clear the pathway ERK1/2 is being regulated by under these basal conditions.
Using the specific EGFR inhibitor erlotinib, ERK1/2 phosphorylation was blocked and
PGC-1α mRNA increased. Thus, EGFR appears to be a key regulator of ERK1/2 which
in turn regulates the basal level of PGC-1α mRNA and its downstream mitochondrial
genes. Nevertheless, it remains to be determined what is activating the EGFR under
these conditions. Possible candidates include EGFR ligands, TGFα and HB-EGF,
and/or transactivation pathways (ADAM17, ANGII, TWEAK/Fn14) (4,40).
Inhibiting ERK1/2 increased PGC-1α mRNA, as well as TFAM, NRF1, and COX1.
The increase in COX1 demonstrates that ERK1/2 is not only increasing nuclear89

encoded gene expression, but also mitochondrial-encoded gene expression. This
response is similar to findings in melanoma cell lines after treatment with various ERK
cascade inhibitors in which an increase in PGC-1α gene expression was observed (41).
Because FOXO3a was not expressed in naïve mouse renal cortex we shifted focus to
FOXO1. FOXO3a and FOXO1 share similar DNA-binding domains, have overlapping
gene expressions (42), and are both directly phosphorylated by ERK1/2 (43).
Phosphorylation of FOXO1 decreased in the nucleus due to ERK1/2 inhibition, which
resulted in an increase in downstream targets of FOXO1 (e.g. catalase and SOD2) and
PGC-1α in the kidney cortex.

During IR-induced AKI in mice, ERK1/2 is highly phosphorylated with accompanying
decreases in PGC-1α and NRF1, as well as a decline in kidney function at 3 hr post IR
surgery. Inhibiting phosphorylated ERK1/2 pre-surgery attenuated the PGC-1α and
NRF1 mRNA decreases and prevented an increase in serum creatinine. We have
previously shown that PGC-1α is rapidly decreased following diverse models of AKI in
mice and rats and these results implicate ERK1/2 as the mediator behind this
transcriptional suppression.

In conclusion we determined the role of ERK1/2 in the physiological and pathological
regulation of renal PGC-1α and MB. We linked EGFR activation and FOXO3a/1
inactivation to the downregulation of PGC-1α and MB, through ERK1/2 signaling.
PGC-1α physiological regulation appears to be structured so that changes can occur
very rapidly when necessary. Finally, ERK1/2 inhibition may have potential in
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preventing mitochondrial dysfunction as a therapeutic strategy in organ dysfunction.
Because mitochondrial injury/recovery and biogenesis can occur throughout different
tissues of the body due to various injury insults we think this therapeutic potential of
inhibiting early activation of ERK1/2 to prevent downregulation of MB may be
applicable to other organs with further studies required.
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EXPERIMENTAL PROCEDURES
In Vitro Studies
Female New Zealand White rabbits (2 kg) were purchased from Charles River
(Oakwood, MI/Canada). Renal proximal tubule cells (RPTC) were isolated using the
iron oxide perfusion method and grown in 35-mm tissue culture dishes under improved
conditions similar to what is observed in vivo, as described previously (44). The culture
medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without
glucose, phenol red, or sodium pyruvate) supplemented with 15 mM HEPES buffer, 2.5
mM L-glutamine, 1 uM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate.
Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5 ug/ml), bovine
insulin (10 nM), and L-ascorbic acid-2-phosphate (50 uM) were added to fresh culture
medium. Confluent RPTC were used for all experiments. RPTC monolayers were
treated with various compounds or vehicle (DMSO) for time points indicated.

In Vivo Studies
Trametinib (GSK1120212, (15)) was purchased from Selleckchem Chemicals (Houston,
TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) mice received an injection
of trametinib (1 mg/kg i.p.) or vehicle control (DMSO). Four hr after injection kidneys
were collected and flash frozen for further analysis.
Mice were assigned to 3 groups: 1) Sham, 2) I/R + Vehicle, 3) I/R + Trametinib.
Vehicle or trametinib were administered i.p 1 hr before surgery. I/R grouped mice were
subjected to I/R surgery by bilateral renal pedicle clamping for 18 min as described
previously (32). Briefly, the renal artery and vein were isolated and blood flow was
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occluded with a vascular clamp for 18min while maintaining a constant body
temperature of 36~37°C. Sham mice were treated exactly the same as I/R mice without
the clamping of the renal pedicles. Mice were euthanized at 3 h after surgery, and blood
and kidneys (flash frozen in liquid nitrogen) were collected for analysis.

RT-qPCR Analysis of mRNA Expression
Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life
Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used
according to the manufacturer’s protocol. The generated cDNA was used with the
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA
expression of all genes was determined by the 2−ΔΔCt method, and mouse Actin RNA
and rabbit tubulin RNA were used as reference genes for normalization (Table 1 for
Primer pairs).

Immunoblot Analysis
Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) with
protease inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium
orthovanadate (Sigma-Aldrich).
Mouse tissue and rabbit primary cells nuclear and cytosolic fraction lysates were
prepared as previously described with modifications (11). Briefly, a piece of kidney
cortex was homogenized in sucrose isolation (ISO) buffer (250 mM sucrose, 1 mM
EGTA, 10 mM HEPES, 1 mg/ml fatty acid-free BSA [pH 7.4]) with a dounce tissue
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grinder. Lysates were centrifuged at 1000 x g for 10 min. The 1st pellet was re-washed
two separate times in ISO buffer and resuspended in RIPA. The 1st supernatant was
centrifuged at 10,000 x g for 5 min for further purification of the cytosol fraction.
Histone H3 and/or Lamin B1 were used as loading control for nuclear lysate
immunoblots, and alpha-tubulin was used for loading control of cytosolic lysates.
Equal protein quantities (20–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved
by gel electrophoresis, and transferred onto nitrocellulose or PVDF membranes (BioRad). Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and
incubated overnight with primary antibody at 4°C with gently agitation. Primary
antibodies used in these studies included (all from Cell Signaling) phospho-ERK1/2
(1:1000) [#4370], total ERK1/2 (1:1000) [#4695], AKT (1:1000) [#9272], phosphoAKT (1:1000) [#4060], phospho-p38 (1:1000) [#4511], p38 MAPK (1:1000) [#8690],
EGF Receptor (1:1000) [#4267], phospho-EGFR Tyr1173 (1:750) [#4407s], phosphoEGFR Tyr1068 (1:1000) [#3777s], total FOXO3a (1:1000), phospho Ser294-FOXO3a
(1:1000) [#5538], and total FOXO1 (1:1000) [#2880] Danvers, MA. Phospho S329FOXO1 (1:1000; Abcam) [ab192201], TFAM (1:1000; Abcam) [ab131607], lamin B1
(1:1000; Abcam) [ab16048], kidney injury molecule-1 (KIM-1) (1:1000; R&D systems,
Minneapolis, MN) [AF1817], histone H3 (1:2000) [#9715], PGC-1α (1:1000; Abcam)
[ab54481], and β-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX) [ sc-47778].
Membranes were incubated with the appropriate horseradish peroxidase–conjugated
secondary antibody before visualization using enhanced chemiluminescence (Thermo
Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was
determined using the ImageJ software from NIH.
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Statistical Analysis
All data are shown as mean ± S.E.M. When comparing two experimental groups, an
unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical
differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc
test was performed for comparisons of multiple groups. P < 0.05 was considered
statistically significant. All statistical tests were performed using GraphPad Prism
software (GraphPad Software, San Diego, CA).
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CHAPTER THREE:
Extracellular Signal-Regulated Kinase 1/2 Regulates Mouse Kidney Injury
Molecule-1 Expression Physiologically and Following Ischemic and Septic Renal
Injury.
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ABSTRACT
The upregulation of kidney injury molecule-1 (KIM-1) has been extensively studied in
various renal diseases and following acute injury; however, the initial mechanisms
controlling KIM-1 expression remain limited. In this study, KIM-1 expression was
examined in mouse renal cell cultures and in two different models of acute kidney
injury (AKI), ischemia reperfusion (IR)–induced and lipopolysaccharide (LPS)-induced
sepsis. KIM-1 mRNA increased in both AKI models, and pharmacological inhibition of
extracellular signal–regulated kinase 1/2 (ERK1/2) signaling attenuated injury-induced
KIM-1 expression in the renal cortex. Toll-like receptor 4 knockout (TLR4KO) mice
exhibited reduced ERK1/2 phosphorylation and attenuated KIM-1 mRNA after LPS
exposure. TLR4KO mice were not protected from IR-induced ERK1/2 phosphorylation
and upregulation of KIM-1 mRNA. Following renal IR injury, phosphorylation of
signal transducer and activator of transcription 3 (STAT3) at serine 727 and tyrosine
705 increased downstream from ERK1/2 activation. Because phosphorylated STAT3 is
a transcriptional upregulator of KIM-1 and inhibition of ERK1/2 attenuated increases in
STAT3 phosphorylation, we suggest an ERK1/2-STAT3-KIM-1 pathway following
renal injury. Finally, ERK1/2 inhibition in naive mice decreased KIM-1 mRNA and
nuclear STAT3 phosphorylation in the cortex, indicating homeostatic regulation of
KIM-1. These findings reveal renal ERK1/2 as an important initial regulator of KIM-1
expression in IR and septic AKI and at a physiologic level (Figure 3.7 – Visual
Abstract).

101

INTRODUCTION
KIM-1 is a type I transmembrane glycoprotein that is rapidly upregulated at the gene
and protein level following various types of injury to the kidney [1-3]. For example,
KIM-1 is increased in IR, cisplatin, sepsis, folic acid, aristolochic acid and gentamicininduced injuries, as well as occurring in disease states, such as renal cell carcinoma,
polycystic kidney disease, hyperoxaluria, and hypertension [4-7].
The ectodomain, which contains an Ig-like domain and a glycosylated mucin domain, is
cleaved by the metalloproteinase ADAM17 at the cellular membrane [3, 8, 9].
Membrane bound KIM-1 and cleaved KIM-1 increase with worsening renal injury [10].
KIM-1 is located on the apical surface of renal proximal tubule epithelial cells and
recognizes phosphatidylserine and oxidized lipoprotein epitopes on the surface of
apoptotic bodies [11].

The extracellular signal-regulated kinase 1/2 (ERK1/2) is a mitogen-activated protein
kinase (MAPK) that is phosphorylated rapidly following renal injury [12-14]. We
previously demonstrated ERK1/2 phosphorylation is elevated 3 hr post IR injury and 1
hr post LPS induced AKI [15, 16]. Further exploration of the ERK1/2 pathway was
performed utilizing a specific MEK1/2 inhibitor, trametinib, which inhibits the increase
in ERK1/2 phosphorylation, since MEK1/2 is directly upstream of ERK1/2 [17, 18].
Interestingly, inhibiting LPS induced ERK1/2 phosphorylation prevented KIM-1
mRNA upregulation at 3 and 18 hr post LPS administration. Smith et al. confirmed
ERK1/2 inhibition attenuates the upregulation of KIM-1 mRNA following injury
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utilizing trametinib treatment 6 hr post cecal ligation and puncture (CLP) surgery, a
model of sepsis [19].

ERK1/2 and KIM-1 were studied in vitro using a porcine kidney epithelial cell line,
LLC-PK1, transfected with human KIM-1 [20]. KIM-1 protein promoted cell migration
and proliferation through activation of the ERK1/2 pathway, and inhibiting ERK1/2
attenuated these processes. Recently, KIM-1 was shown to modulate macrophages by
promoting an M1 phenotype and macrophage migration by MAPK pathways, including
ERK, p38, and JNK [6]. It is clear that ERK1/2 and KIM-1 are activated and
upregulated shortly after kidney injury, however a direct connection between ERK1/2
and KIM-1 has received limited study.

Ajay et al. used a combination of bioinformatics, in vitro, and in vivo experiments to
determine that signal transducer and activator of transcription-3 (STAT3)
phosphorylation at serine 727 (S727) and tyrosine 705 (Y705) increases KIM-1
transcription by binding to the KIM-1 specific promoter [21]. Checkpoint kinase 1
(Chk1) was upregulated following IR injury due to DNA damage which phosphorylated
STAT3 and subsequently regulated KIM-1 expression [21]. Interestingly, ERK2 was
the most enriched upstream kinase identified that was associated with the highest
upregulated transcription factors following IR injury [21-23]. Given this information
and our previous data demonstrating ERK1/2 is rapidly phosphorylated post IR injury,
we hypothesized early ERK1/2 activation following injury preferentially regulates
KIM-1 expression.
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MATERIALS AND METHODS
In Vitro Studies.
A transgenic kidney proximal tubule (TK) cell line originally isolated from
8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss, was used in all in
vitro experiments [24, 25]. TK cells were grown in 35-mm tissue culture dishes. The
culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12
(without phenol red, or sodium pyruvate) supplemented with 5mM glucose, 10% FBS,
15 mM HEPES buffer, 2.5 mM L-glutamine, 1 uM pyridoxine HCl, 15 mM sodium
bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human
transferrin (5 ug/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (50 uM)
were added to fresh culture medium. 90-95% confluent TK cells were used for all
experiments, and FBS was removed from culture media 24 hr before experimentation.
TK cell monolayers were treated HU (Fisher Scientific- AC151680050), TBHP (Sigma#458139), and H2O2 (Sigma- H1009) or vehicle (DMSO-Sigma) for time points
indicated. Different TK cell passages used on different days represent the “N” value for
the in vitro studies.

Naïve and AKI Studies.
Trametinib (GSK1120212, [18]) was purchased from Selleckchem Chemicals (Houston,
TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) were acquired from Charles
River Laboratories (Frederick, MD) and received an injection of trametinib (1 mg/kg
i.p.) or vehicle control (NEOBEE M-5 – Fisher Scientific). Four hr after injection
kidneys were collected and flash frozen in liquid nitrogen for further analysis.
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For IR AKI, mice were assigned to 3 groups: 1) Sham, 2) IR + Vehicle, 3) IR +
Trametinib. Vehicle or trametinib were administered i.p 1 hr before surgery. For
TLR4KO IR AKI mice were assigned to 4 groups: 1) WT sham, 2) TLR4KO SHAM, 3)
WT IR, 4) TLR4KO IR. IR grouped mice were subjected to IR surgery by bilateral
renal pedicle clamping for 18.5 min as described previously [26]. Briefly, the renal
artery and vein were isolated and blood flow was occluded with a vascular clamp for
18.5 min while maintaining a constant body temperature of 36~37°C. Sham mice were
treated exactly the same as IR mice, except without the clamping of the renal pedicles.
Mice were euthanized at 3 or 24 hr after surgery, and blood and kidneys (flash frozen in
liquid nitrogen) were collected for analysis.
For LPS model of sepsis, eight week old male C57BL/6 mice (20–25 g) were given an
i.p injection of 10 mg/kg LPS derived from Escherichia coli serotype O111:B4 (SigmaAldrich, St. Louis, MO). Control mice received an i.p injection of an equal volume of
0.9% normal saline. Mice received an injection of GSK1120212 (1 mg/kg i.p.) or
vehicle control 1 hr before administration of LPS. Mice were euthanized at 18 hr after
LPS exposure, and kidneys and blood were collected for analysis. Experiments with
TLR4KO mice were graciously donated by Dr. Kenneth D. Chavin and generated by
crossing C57BL/10ScN mice with the tlr4LPS-d mutation onto the C57BL/6
background for at least five generations [16, 27]. All studies were conducted in
accordance with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Animal use was approved by the
Institutional Animal Care and Use Committee at the Medical University of South
Carolina.
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Serum Creatinine Measurement.
Blood was collected by retro-orbital bleeding puncture and allowed to sit at room
temperature for 30 minutes. The samples were centrifuged at 10,000 rpm for 10 min to
separate the serum. Serum creatinine (SCr) was determined using the Creatinine
Enzymatic Reagent Assay kit (Pointe Scientific, Canton, MI) [c7548-120] based on the
manufacturer’s directions. All values are expressed as serum creatinine concentration in
milligrams per deciliter.

RT-qPCR Analysis of mRNA Expression.
Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life
Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used
according to the manufacturer’s protocol. The generated cDNA was used with the
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA
expression of all genes was determined by the 2−ΔΔCt method, and mouse Actin RNA
and rabbit tubulin RNA were used as reference genes for normalization. KIM-1 primer
sequences used were Fwd- 5’-GCATCTCTAAGCGTGGTTGC-3’ and Rev- 5’TCAGCTCGGGAATGCACAA-3’.

Immunoblot Analysis.
Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) with
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protease inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium
orthovanadate (Sigma-Aldrich).
Mouse tissue nuclear and cytosolic fraction lysates were prepared as previously
described (24096033, 27875304). Briefly, a piece of kidney cortex was homogenized in
sucrose isolation (ISO) buffer (250 mM sucrose, 1 mM EGTA, 10 mM HEPES, 1
mg/ml fatty acid-free BSA [pH 7.4]) added fresh, with a dounce tissue grinder. Lysates
were centrifuged at 1000 x g for 10 min. The 1st pellet was pushed through 25G needle
3 times and re-washed three separate times in ISO buffer and resuspended in RIPA. The
1st supernatant was centrifuged at 10,000 x g for 5 min for further purification of the
cytosol fraction. Histone H3 and/or Lamin B1 were used as loading control for nuclear
lysate immunoblots, and alpha-tubulin was used for loading control of cytosolic lysates.
Equal protein quantities (10–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved
by gel electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad).
Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and
incubated overnight with primary antibody at 4°C with gently agitation. Primary
antibodies used in these studies included phospho-ERK1/2 (1:1000) [#4370], total
ERK1/2 (1:1000) [#4695], phospho-Chk1 (1:1000) [#12302], Chk1 (1:1000) [#2360],
phospho-STAT3-Tyr705 (1:1000) [#9145], phospho-STAT3-Ser727 (1:1000) [#94994],
total STAT3 (1:1000) [#9139], Histone H3 (1:2000) [#9715] all from Cell Signaling
Technology, Danvers, MA. lamin B1 (1:1000; Abcam) [ab16048], phospho-Chk1
(1:800) [AF2054], kidney injury molecule-1 (KIM-1) (1:1000) [AF1817] from R&D
systems, Minneapolis, MN. β-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX) [
sc-47778].
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Membranes were incubated with the appropriate horseradish peroxidase–conjugated
secondary antibody before visualization using enhanced chemiluminescence (Thermo
Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was
determined using the ImageJ software from NIH and Image Studio Lite from LI-COR.

Statistical Analysis.
All data are shown as mean ± S.E.M. When comparing two experimental groups, an
unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical
differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc
test was performed for comparisons of multiple groups. P < 0.05 was considered
statistically significant. All statistical tests were performed using GraphPad Prism
software (GraphPad Software, San Diego, CA).
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RESULTS
ERK1/2 Increases KIM-1 mRNA Following Toxicant Exposure in Mouse Renal
Cells.
To confirm KIM-1 expression is upregulated following toxicant exposure, cultured
transgenic mouse kidney proximal tubule (TK) cells were treated with 1 and 10 mM
hydroxyurea (HU), 0.1 and 1 mM hydrogen peroxide (H2O2), and 350 and 700 µM
tert-butyl hydroperoxide (TBHP) for 24 hr. HU causes cellular injury by inhibiting
DNA synthesis and causing DNA damage [28], while H2O2 and TBHP are model
oxidants that lead to oxidative stress causing protein, lipid, and DNA damage [29]. Each
toxicant increased KIM-1 mRNA with increasing concentration (Figure 3.1A). KIM-1
mRNA increased 8-, 3-, and 3-fold in response to 10 mM HU, 1 mM H2O2, and 700
µM TBHP, respectively (Figure 3.1A). A 1 hr pretreatment with trametinib prevented
HU, H2O2, and TBHP induced KIM-1 mRNA increases (Figure 3.1B). Interestingly,
TK cells treated with trametinib alone showed a 54% decrease in KIM-1 mRNA
compared to vehicle control cells at 24 hr (Figure 3.1B). These data reveal a regulatory
role for ERK1/2 on KIM-1 mRNA under control conditions and following DNA and
oxidative damage.
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Figure 3.1: ERK1/2 increases KIM-1 mRNA after toxicant exposure in mouse
TKPT cells. (A) KIM-1 mRNA expression after 24 hr following exposure to HU,
H2O2, and TBHP. (B) KIM-1 mRNA measured after 24 hr post toxicant
administration with or without 1 hour trametinib (GSK) pretreatment. Data are
represented as mean ± S.E.M., n ≥ 4. Superscripts indicate statistically significant
differences (P < 0.05);*, significantly different than vehicle control; #, significance
between same toxicant groups.
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Early ERK1/2 Activation Mediates STAT3 Phosphorylation Induced KIM-1
mRNA Upregulation Following IR AKI.
KIM-1 mRNA increased 4.7-fold 3 hr post IR AKI compared to sham controls (Figure
3.2A). Trametinib attenuated the KIM-1 mRNA and serum creatinine increases when
administered 1 hr before IR surgery (Figure 3.2A, 2B). The phosphorylated ERK1/2 to
total ERK1/2 ratio increased 4.5-fold in the IR groups compared to sham (Figure 3.2C,
2D). Trametinib also completely inhibited ERK1/2 phosphorylation increases following
AKI, as observed previously [15, 16].
Ajay et al. (2014) reported that Chk1 phosphorylation is elevated 3 hr post IR AKI. In
contrast, we did not observe any change in phosphorylated Chk1 to total Chk1 ratio
following IR injury in the presence or absence of trametinib. However, transcription
factor STAT3 phosphorylation at both activating sites, S727 and Y705, increased 2.5and 3.5-fold after renal IR, respectively (Figure 3.2C, 2E-H) and pretreatment with
trametinib partially blocked the increase in phosphorylation of STAT3 at S727 and
Y705 (Figure 3.2G, 2H). These findings suggest that inhibiting ERK1/2
phosphorylation prevents KIM-1 mRNA upregulation 3 hr post IR AKI by preventing
STAT3 phosphorylation at S727 and Y705.
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Figure 3.2: ERK1/2 mediates
STAT3 phosphorylation and
KIM-1 mRNA upregulation
following 3 hr of IR AKI. (A)
KIM-1 mRNA expression
following IR AKI after 3 hr. (B)
Serum creatinine was assessed 3
hr after IR AKI. (C)
Representative immunoblot of
phosphorylated ERK1/2, total
ERK1/2, phosphorylated Chk1,
and total Chk1 following 3 hr of
IR AKI. (D) Densitometry
analysis of phosphorylated
ERK1/2 compared with total
ERK1/2. (E) Densitometry
analysis of phosphorylated Chk1
compared with total Chk1. (F)
Representative immunoblot of
phosphorylated STAT3 (S727 and
Y705) and total STAT3 following
3 hr of IR AKI. (G and H)
Densitometry analysis of
phosphorylated STAT3 (S727 and
Y705) compared with total
STAT3. Data are represented as
mean ± S.E.M., n = 6. Different
superscripts indicate statistically
significant differences (P < 0.05).
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ERK1/2 Inhibition Suppresses KIM-1 mRNA and Protein 24 hr Following IR AKI.
At 24 hr, KIM-1 mRNA was ~280-fold higher in the IR group compared to sham
controls (Figure 3.3A). Trametinib partially blocked the increase in KIM-1 mRNA
(~120-fold higher compared to sham) compared to the IR mice (Figure 3.3A). Serum
creatinine increased to 1.1 mg/dL in the IR group and pretreatment with trametinib
attenuated this rise in serum creatinine at 24 hr (Figure 3.3B). STAT3 phosphorylation
at S727 and Y705 increased following renal IR injury and trametinib pretreatment
blocked these increases (Figure 3.3D, G-H). Chk1 phosphorylation decreased in the IR
group at 24 hr and ERK1/2 inhibition had no influence on Chk1 phosphorylation
(Figure 3.3D, 3.3F). Trametinib inhibited ERK1/2 phosphorylation throughout the 24
hr period after IR surgery (Figure 3.3D, 3.3E). The IR group showed a large
upregulation in KIM-1 kidney cortex protein that was markedly reduced in the presence
of trametinib at 24 hr (Figure 3.3C). Because KIM-1 is cleaved from the cell surface,
KIM-1 protein was measured in the serum to detect any changes in cleavage regulation
[30]. Serum KIM-1 protein was high in the IR group and was markedly reduced in the
trametinib group (Figure 3.3C). These findings reveal ERK1/2 remains activated 24 hr
following IR AKI, which corresponds to increased phosphorylation of STAT3 at S727
and Y705, and leads to increases in KIM-1 mRNA and protein. This correlates with our
observations of STAT3 phosphorylation at S727 and Y705 in the trametinib group
compared to the IR group in our 3 hr study (Figure 3.2F-H). It is clear, however, that
ERK1/2 and STAT3 are not the only pathway responsible for the later increases in
KIM-1 mRNA, as the trametinib group is only partially attenuated at 24 hr (Figure
3.3A).
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Figure 3.3: ERK1/2 mediates KIM-1 mRNA and protein increases and STAT3
phosphorylation following 24 hr of IR AKI. (A) KIM-1 mRNA expression
following IR AKI after 24 hr. (B) Serum creatinine was assessed 24 hr after IR AKI.
(C) Representative immunoblot of renal KIM-1 and serum KIM-1 (n = 2 for serum
KIM-1) following 24 hr of IR AKI. (D) Representative immunoblot of
phosphorylated ERK1/2, total ERK1/2, phosphorylated STAT3 (S727 and Y705),
total STAT3, phosphorylated Chk1, and total Chk1 following IR AKI. (E–H)
Densitometry analysis of phosphorylated (E) ERK1/2 to total ERK1/2; (F) p-Chk1 to
total Chk1; (G) p-STAT3 S727 to total STAT3; (H) p-STAT3 Y705 to total STAT3.
Data are represented as mean ± S.E.M., n ≥ 5, except where indicated. Different
superscripts indicate statistically significant differences (P < 0.05).
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ERK1/2 Increases KIM-1 mRNA in Sepsis Induced AKI and Requires TLR4.
Previously, we demonstrated LPS-induced AKI requires TLR4 mediated ERK1/2
activation at the initiation of injury to impair kidney function through mitochondrial
dysfunction and inflammatory cytokines [16]. Similarly, partial attenuation of KIM-1
mRNA upregulation through ERK1/2 inhibition prior to LPS administration at 18 hrs
was observed [16]. Here, trametinib treatment prevented KIM-1 protein upregulation
within the kidney cortex compared to LPS alone at 18 hr (Figure 3.4A). ERK1/2
phosphorylation was inhibited in the trametinib + LPS group compared to the control
and LPS group, whereas the LPS group was not different from controls (Figure 3.4A,
4B). To further illustrate pharmacological ERK1/2 inhibition downregulates KIM-1
expression, ERK1/2 phosphorylation was studied following LPS in TLR4KO mice, as
TLR4 is required for LPS-induced kidney dysfunction [16]. TLR4KO mice had reduced
ERK1/2 phosphorylation compared to WT mice administered LPS (Figure 3.4D, F).
LPS induced increases in KIM-1 mRNA and KIM-1 protein were attenuated in LPS
treated TLR4KO mice, connecting ERK1/2 activation and KIM-1 to TLR4 (Figure
3.4D, E). For confirmation, TLR4 mRNA expression in the TLR4KO mice was
negligible compared to WT TLR4 mRNA expression (Figure 3.4C).
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Figure 3.4: ERK1/2 increases KIM-1 mRNA and protein in LPS-induced AKI
through TLR4 after 18 hr. (A) Representative immunoblot of KIM-1,
phosphorylated ERK1/2, and total ERK1/2 following LPS-induced AKI. (B)
Densitometry analysis of phosphorylated ERK1/2 compared with total ERK1/2. (C)
TLR4 mRNA measured in WT mice kidney and TLR4KO mice kidney. (D)
Representative immunoblot of KIM-1, phosphorylated ERK1/2, and total ERK1/2
following LPS-induced AKI in WT and TLR4KO mice. (E) KIM-1 mRNA
measured in the kidneys of WT and TLR4KO mice following LPS-induced AKI
after 18 hr. (F) Densitometry analysis of renal phosphorylated ERK1/2 compared
with total ERK1/2 in the LPS-treated WT and TLR4KO mice. Data are represented
as mean ± S.E.M., n ≥ 3. Different superscripts indicate statistically significant
differences (P < 0.05).

116

TLR4 is Not Required for IR-Induced ERK1/2 Phosphorylation and KIM-1
mRNA Upregulation.
To determine if ERK1/2 and KIM-1 are regulated by TLR4 during initiation of injury
following IR AKI, TLR4KO mice were subjected to IR surgeries and KIM-1 alterations
were observed at 3 hr. The WT and TLR4KO mice had similar increases in
phosphorylated ERK1/2 following IR AKI compared to their sham controls (Figure
3.5A, 5C). Interestingly, KIM-1 mRNA was markedly elevated in the TLR4KO IR mice
and WT IR mice trended upward (Figure 3.5B). The above findings demonstrate that IR
AKI induced KIM-1 upregulation and ERK1/2 activation are TLR4 independent.
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Figure 3.5: TLR4 is not required for IR-induced ERK1/2 phosphorylation and
KIM-1 mRNA upregulation. (A) Representative immunoblot of phosphorylated
ERK1/2 and total ERK1/2 following IR-induced AKI after 3 hr in WT and TLR4KO
mice. (B) KIM-1 mRNA measured in the kidneys of WT and TLR4KO mice
following IR-induced AKI after 3 hr. (C) Densitometry analysis of renal
phosphorylated ERK1/2 compared with total ERK1/2 in the WT and TLR4KO mice
following IR-induced AKI. Data are represented as mean ± S.E.M., n ≥ 3. Different
superscripts indicate statistically significant differences (P < 0.05).
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ERK1/2 Inhibition Decreases KIM-1 mRNA, and Nuclear and Cytosolic STAT3
Phosphorylation Under Physiological Conditions.
To determine if ERK1/2 regulates KIM-1 at a physiological level, naïve mice were
treated with trametinib or vehicle for 4 hr. Unexpectedly, trametinib treated mice had
~55% lower KIM-1 mRNA compared to vehicle control mice (Figure 3.6A). The
trametinib group had reduced ERK1/2 phosphorylation in the nucleus and cytosol
(Figure 3.6G, H). Nuclear STAT3 phosphorylation at sites Y705 and S727 were down
in the trametinib group 55% and 46%, respectively, compared to the vehicle control
group (Figure 3.6B-D). Phosphorylated Y705 and S727 on STAT3 in the cytosol was
also reduced in the trametinib group (Figure 3.6E, F). To confirm that trametinib was
inhibiting nuclear STAT3 phosphorylation, and subsequently KIM-1 mRNA
downregulation, cytosol and nuclear fractions were isolated and confirmed for purity
using α-tubulin and lamin B1 (Figure 3.6H). The purified fractions demonstrated that
inhibition of physiological ERK1/2 phosphorylation results in a decrease in KIM-1
mRNA through reducing STAT3 phosphorylation at Y705 and S727 in the kidney. By
decreasing active STAT3 within the nucleus there is potential for less KIM-1 promoter
binding, resulting in lower KIM-1 mRNA expression.
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Figure 3.6: ERK1/2 inhibition decreases KIM-1 mRNA and nuclear and
cytosolic STAT3 phosphorylation under physiologic conditions in naive mice.
(A) Representative immunoblot of nuclear phosphorylated STAT3 (S727 and Y705)
and total STAT3 in naive mice after 4-hour treatment with trametinib. (B) KIM-1
mRNA measured at 4 hr post-treatment with trametinib. (C and D) Densitometry
analysis of nuclear phosphorylated STAT3 (S727 and Y705) compared with total
STAT3. (E) Representative immunoblot of cytosol phosphorylated STAT3 (S727
and Y705) and total STAT3 in naive mice after 4-hour treatment with trametinib. (F)
Densitometry analysis of cytosol phosphorylated STAT3 (S727 and Y705)
compared with total STAT3. (G) Densitometry analysis of nuclear and cytosol
phosphorylated ERK1/2 compared with total ERK1/2. (H) Representative and
verification renal immunoblot of nuclear and cytosol control proteins with and
without trametinib treatment. Data are represented as mean ± S.E.M., n ≥ 6.
Different superscripts indicate statistically significant differences (P < 0.05).
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Figure 3.7: Visual Abstract. Proposed mechanism of IR, LPS, and ROS-induced
renal damage that initiates ERK1/2 and STAT3 phosphorylation. STAT3 then binds
to the KIM-1 promoter and increases KIM-1 mRNA. By preventing ERK1/2
phosphorylation following renal injury, STAT3 phosphorylation is decreased,
leading to less phosphorylated STAT3 within the nucleus, and subsequently less
KIM-1 mRNA increases post injury.
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DISCUSSION
In this study, ERK1/2 was identified as a regulator of KIM-1 expression. ERK1/2
inhibition prevented KIM-1 transcription in vitro following toxicant exposure, and
attenuated increases in KIM-1 mRNA and protein in IR AKI. STAT3 phosphorylation
at S727 and Y705 decreased as a result of ERK1/2 inhibition, leading to less KIM-1
expression. In sepsis-induced AKI, TLR4 was required for activation of ERK1/2 and
KIM-1 upregulation. In contrast, ERK1/2 phosphorylation following IR AKI was not
dependent on TLR4. Interestingly, in naïve mice ERK1/2 regulates KIM-1 mRNA by
physiological STAT3 phosphorylation in the nucleus. We suggest ERK1/2 regulates
renal KIM-1 expression at a physiological level and initially during pathological renal
injury by phosphorylation of STAT3.
The discovery that KIM-1 is the most upregulated gene following AKI led to an
increase in KIM-1 renal research [2, 3, 31]. Ajay et al. explored the signaling pathway
that results in upregulation of renal KIM-1 transcription. They reported KIM-1
transcriptional regulation by Chk1-STAT3 interaction following AKI-induced DNA
damage. Chk1 was revealed as an upstream kinase of STAT3 and phosphorylation at
S727 and Y705 on STAT3 was required for KIM-1 upregulation [21]. Phosphorylated
STAT3 increased following AKI and was found to bind to the KIM-1 promoter,
therefore increasing KIM-1 mRNA and protein [21]. While our studies support the
work of Ajay et al., important differences were observed. (1) Chk1 phosphorylation did
not increase following IR AKI at 3 and 24 hr. (2) ERK1/2 was responsible for the
STAT3 phosphorylation after IR. (3) Our IR experimental design utilized mice rather
than rats for AKI. Chk1 phosphorylation did not increase in the renal cortex in our
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experiments, yet, KIM-1 mRNA and renal dysfunction was observed. Nevertheless,
STAT3 phosphorylation was verified to increase following renal injury, and a reduction
in phosphorylated STAT3 attenuated KIM-1 mRNA. However, ERK1/2 was
demonstrated as the key initial regulator of STAT3 phosphorylation following renal
injury, rather than Chk1.
We previously published work demonstrating that inhibiting the rapid activation of
ERK1/2 following renal injury prevents and/or attenuates injury and dysfunction
through restoration of mitochondrial function, renal microvascular perfusion, and
attenuation of pro-inflammatory cytokines [15, 16, 19]. Here, ERK1/2 involvement with
STAT3 after renal injury was observed. STAT3 phosphorylation is activated early in
tubule cells following injury, although the exact role in kidney dysfunction and
recovery varies in different AKI models [32, 33]. For example, in HgCl2, IR, and
aristolochic acid induced AKI, early STAT3 phosphorylation was protective [34, 35]. In
contrast, inhibition of STAT3 phosphorylation in polycystic kidney disease, unilateral
ureteral obstruction, and HIV-associated nephropathy has shown beneficial outcomes
[36-38]. Our findings suggest that prevention of renal IR-induced STAT3
phosphorylation through ERK1/2 inhibition attenuates serum creatinine and KIM-1
expression.
Previous experiments demonstrated activated ERK1/2 phosphorylates STAT3 at S727,
while at the same time decreasing STAT3 Y705 phosphorylation [39-41]. However, in
our study both S727 and Y705 phosphorylation increased following IR injury and
decreased with pretreatment with trametinib, suggesting ERK1/2 is responsible for
phosphorylating both sites. At 24 hr following IR AKI, a partial reduction of KIM-1
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mRNA in the trametinib group was observed, along with a complete attenuation of
serum creatinine elevation compared to the IR group. KIM-1 protein levels were
substantially lower in the trametinib treated mice, both in the kidney cortex and in the
circulatory system, as KIM-1 can be detected in the blood. This occurrence has been
recognized due to the loss of cell polarity, microvascular permeability dysfunction,
disruption of cell-cell adhesion junctions, and basement membrane cell detachment [6,
30].
ERK1/2 phosphorylation was found to regulate KIM-1 expression in a second AKI
model. LPS-induced AKI increased ERK1/2 phosphorylation and KIM-1 protein,
whereas trametinib prevented ERK1/2 activation and attenuated the KIM-1 protein
increase. Further characterization of the ERK1/2-KIM-1 pathway was demonstrated by
utilization of TLR4KO mice. TLR4 is required for LPS-induced ERK1/2
phosphorylation and subsequently, KIM-1 mRNA upregulation [16]. ERK1/2 is rapidly
phosphorylated following LPS at 1 and 3 hr, however in this study, at 18 hr post-LPS
phosphorylated ERK1/2 was not different than the control group, most likely stemming
from a prompt compensatory mechanism. Nonetheless, 18 hr after CLP, which is a
slower developing sepsis model, ERK1/2 phosphorylation is still highly phosphorylated
compared to controls [16, 19]. To verify that TLR4 signaling was not regulating KIM-1
expression directly, the TLR4KO mice underwent IR AKI and were compared to the
wild type mice. There were no differences in ERK1/2 phosphorylation between the
TLR4KO IR group and the WT IR group, and the TLR4KO group had increased KIM-1
mRNA. Thus, TLR4 is required for LPS induced ERK1/2 activation and increase in
KIM-1 mRNA, yet in IR AKI TLR4 is not required since ERK1/2 is activated via other
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non-TLR4 upstream pathways. Therefore, we view ERK1/2 phosphorylation as a key
event controlling KIM-1 regulation, and is activated through different pathways in
different diseases.
To determine if ERK1/2 regulated KIM-1 at a physiological level, trametinib was
administered to naïve mice. Although KIM-1 is expressed at very low levels in healthy
non-injured kidneys, there is a physiological basal level of detection [3, 42]. In the
absence of an injury, inhibiting physiological ERK1/2 phosphorylation resulted in the
downregulation of KIM-1 mRNA. This observation correlates with our in vitro results
that demonstrated trametinib treatment in mouse TK cells decreased KIM-1 mRNA.
Phosphorylated Chk1 was not altered in the trametinib treated mice (data not shown).
ERK1/2 phosphorylation was inhibited in the nuclear and cytosolic fractions of the
kidney cortex, which decreased STAT3 Y705 and S727 phosphorylation in the nucleus.
Therefore, less active STAT3 is able to bind to the KIM-1 promoter, corresponding to
the KIM-1 mRNA reduction observed.
We have provided evidence that STAT3 phosphorylated at Y705 and S727 are partially
responsible for renal KIM-1 upregulation, and that ERK1/2 involvement is upstream of
STAT3. These findings provide further evidence that initial ERK1/2 activation is a key
regulator of various pathways following renal injury, which may lead to the discovery
of potential pharmacological based therapies.
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CHAPTER FOUR:
ERK1/2 Regulates NAD+ Metabolism During Acute Kidney Injury Through
microRNA-34a-Mediated NAMPT Expression
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ABSTRACT
Prior studies have established the important role of extracellular signal-regulated kinase
1/2 (ERK1/2) as a mediator of acute kidney injury (AKI). We demonstrated rapid
ERK1/2 activation induced renal dysfunction following ischemia/reperfusion (IR)induced AKI and downregulated the mitochondrial biogenesis (MB) regulator,
peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) in mice. In this
study, ERK1/2 regulation of cellular NAD+ and PGC-1α were explored. Inhibition of
ERK1/2 activation using the MEK1/2 inhibitor, trametinib, attenuated renal cortical
NAD+ depletion after AKI in mice. The rate-limiting NAD biosynthesis salvage
enzyme, NAMPT, decreased following AKI, and this decrease was prevented by
ERK1/2 inhibition. The microRNA miR-34a decreased with the inhibition of ERK1/2,
leading to increased NAMPT protein. Treating mice with a miR34a mimic prevented
increases in NAMPT protein in the renal cortex in the presence of ERK1/2 inhibition. In
addition, ERK1/2 activation increased acetylated PGC-1α, the less active form, whereas
inhibition of ERK1/2 activation prevented an increase in acetylated PGC-1α after AKI
through SIRT1 and NAD+ attenuation. These results implicate IR-induced ERK1/2
activation as an important contributor to the downregulation of both PGC-1α and NAD+
pathways that ultimately decrease cellular metabolism and renal function. Inhibition of
ERK1/2 activation prior to the initiation of IR injury attenuated decreases in PGC-1α
and NAD+ and prevented kidney function.
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INTRODUCTION
Extracellular regulated kinases 1/2 (ERK1/2) are protein-serine/threonine kinases that
are activated through phosphorylation by the upstream mitogen-activated protein kinase
kinase 1/2 (MEK1/2) [1, 2]. This signaling pathway is initiated by various extracellular
stimuli and intracellular signaling that ultimately targets several physiological and
pathological pathways [3, 4]. Many reviews have covered the cellular processes that
ERK1/2 is known to participate, such as proliferation, differentiation, cell survival,
migration, death, and metabolism [2, 5-9]. Because ERK1/2 regulates a broad array of
processes, and many of these processes are seemingly opposite in nature, context is very
important in ERK1/2 signaling.
We previously demonstrated rapid ERK1/2 activation following renal ischemiareperfusion (IR) injury downregulates mitochondrial biogenesis (MB) by decreasing
PGC-1α, the master regulator of MB, and the downstream targets of MB expression in
renal cortical epithelial cells [10]. This is especially relevant as epithelial cells of the
proximal tubules have a high mitochondrial content to produce ATP that drives various
transport processes. This is not unique to the epithelial cells of the kidney, as the
epithelium of the intestine, lung (alveolar type II cell), and the liver (hepatocytes)
require mitochondria for their energy demands [11-14]. To meet the energy demands,
renal proximal tubules rely on mitochondrial oxidative phosphorylation exclusively and
any mitochondrial dysfunction can disrupt the energy balance resulting in cellular
injury/death and prevent recovery from injury [15, 16].
PGC-1α is a transcriptional coactivator involved in the regulation of cellular and
mitochondrial metabolism through a number of pathways that include MB,
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mitochondrial dynamics, and mitophagy [17-19]. PGC-1α is enriched in tissues with
high mitochondrial content and energy demands, such as the heart, skeletal muscle, and
kidney [20-22]. Specifically, PGC-1α is highly expressed in the renal cortical epithelial
cells and has been demonstrated to play a vital protective role in multiple diverse renal
diseases, including sepsis, IR injury, diabetes, and fibrosis [19].
Using the potent and specific MEK1/2 inhibitor, trametinib, we blocked ERK1/2
phosphorylation in the kidney of naive mice and observed increases in PGC-1α and
downstream targets of PGC-1α, including nuclear-encoded mitochondrial transcription
factor A (TFAM) and nuclear respiratory factor-1 (NRF1), and the mitochondrialencoded electron transport chain protein cytochrome c oxidase I (COX1) [10]. ERK1/2
activation due to IR injury was inhibited by trametinib pretreatment, and attenuated
PGC-1α mRNA and protein loss, ultimately preventing a rise in serum creatinine, a
marker of renal dysfunction. Similarly, ERK1/2 inhibition also prevented the
downregulation of renal PGC-1α in a lipopolysaccharide (LPS)-induced sepsis model in
mice and attenuated kidney dysfunction [23].
Overexpression of PGC-1α in cultures of primary rabbit renal proximal tubule epithelial
cells (RPTC) promoted mitochondrial and cellular recovery following oxidant injury
[24]. Similar results were obtained in RPTC using a pharmacological compound,
formoterol, which acts through the β 2 -adrenergic receptor to increase PGC-1α
expression leading to an increase in maximal oxygen consumption rate and MB. In vivo
PGC-1α upregulation using formoterol increased mitochondrial electron transport chain
proteins and improved renal recovery following IR injury [25, 26].
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NAD+ is a vital coenzyme used in cellular energy metabolism, redox signaling, and
contributes to overall cellular health [27, 28]. NAD+ is often depleted during injury or
disease, and restoration or prevention of this depletion averts worsening injury and
often promotes recovery [29]. The kidney is highly susceptible to NAD+ depletion as it
has the lowest NAD+ half-life at ~30 min, yet is also among the highest NAD+
containing organs [30].
Tran et al. reported a connection between PGC-1α and nicotinamide adenine
dinucleotide (NAD) metabolism [31, 32]. Utilizing both PGC-1α knockout and
overexpressing transgenic mice, the group determined that PGC-1α is required for less
severe AKI, including improved renal recovery and increased survival. Additionally,
the group found that PGC-1α-mediated AKI protection was largely due to the
prevention of NAD+ depletion through upregulation of the de novo NAD+ pathway.
Exogenous nicotinamide (NAM) administered to PGC-1α KO mice improved renal
function after injury by increasing the NAD+ pool [31].
The importance of NAD+ in the kidney was also confirmed by Guan et al., by
preventing NAD+ depletion and renal dysfunction in both cisplatin and IR injuryinduced AKI in 3 and 20 month old mice by administering nicotinamide
mononucleotide (NMN), a NAD+ precursor [33]. NMN also restored NAD+ and SIRT1
levels [33]. Age associated AKI microarray data pointed to MAPK signaling as an
important contributor following cisplatin injury, possibly connecting MAPK signaling
and NAD. However, less is known about the interactions between ERK1/2 and NAD+
metabolism in the proximal tubules and kidney. Considering the important roles of
ERK1/2, PGC-1α, and NAD+ physiologically and pathologically, and our previous
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reports of ERK1/2 regulation on renal PGC-1α, we hypothesized early ERK1/2
activation following IR-induced AKI regulates NAD+ metabolism.
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MATERIALS AND METHODS
In Vitro Studies.
Female New Zealand White rabbits (2 kg) were purchased from Charles River
(Oakwood, MI/Canada). Renal proximal tubule cells (RPTC) were isolated using the
iron oxide perfusion method and grown in 35-mm tissue culture dishes under improved
conditions similar to what is observed in vivo [34]. The culture medium was a 1:1
mixture of Dulbecco’s modified Eagle’s medium/F-12 (without glucose, phenol red, or
sodium pyruvate) supplemented with 15 mM HEPES buffer, 2.5 mM L-glutamine, 1
uM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50
nM), selenium (5 ng/ml), human transferrin (5 ug/ml), bovine insulin (10 nM), and Lascorbic acid-2-phosphate (50 uM) were added to fresh culture medium. Confluent
RPTC were used for all experiments. RPTC monolayers were treated with various
compounds or vehicle (DMSO).
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Naïve and AKI Studies.
Trametinib (GSK1120212 [35]) was purchased from Selleckchem Chemicals (Houston,
TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) were acquired from Charles
River Laboratories (Frederick, MD) and received an injection of trametinib (1 mg/kg)
or vehicle control (NEOBEE M-5 – Fisher Scientific) intraperitoneally (ip). Four hr
after injection, kidneys were collected and flash frozen in liquid nitrogen for further
analysis.
For IRI-induced AKI, mice were assigned to 3 groups: 1) Sham, 2) IR + Vehicle, 3) IR
+ trametinib. Vehicle or trametinib were administered ip 1 hr before surgery. In some
experiments (Figure 3.5), mice were pretreated 48 and 24 hr before IR surgery with
vehicle, FK866 (20 mg/kg) (Selleckchem) [S2799], or NMN (500 mg/kg) (SigmaAldrich) [N3501] by ip injection [36]. IRI mice were subjected to ischemia/reperfusion
surgery by bilateral renal pedicle clamping for 18.5 min as described previously [37].
Briefly, the renal artery and vein were isolated and blood flow was occluded with a
vascular clamp while maintaining a constant body temperature of 36.5~37.5°C. Sham
mice were treated the same as IRI mice, except the renal pedicles were not clamped.
Mice were euthanized at 3 or 24 hr after surgery, and blood and kidneys (flash frozen in
liquid nitrogen) were collected for analysis.

Retro-Orbital Injection of microRNA 34a Mimic.
Polyplus transfection (Illkirch, France) delivery reagent, in vivo-jetPEI, was used for
delivering microRNA 34a mimic to the kidney. Preparation of delivery reagent was
carried out according to manufacturer’s instructions. A 5% glucose solution mixed with
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in vivo-jetPEI was added to a 5% glucose solution containing mirVana miRNA 34a
mimic. Combined solutions were vortexed and allowed to incubate at RT for 15-20 min.
Retro-orbital injection was performed using a solution containing 40 ug of miR34a
mimic and a N/P ratio of 8. An ip injection of vehicle control (NEOBEE M-5) or
trametinib (1 mg/kg) was administered 2 hr later. Mice were euthanized 6 hr following
retro-orbital injection. Mice were assigned 3 groups: 1) jetPEI (retro-orbital) + Vehicle
(ip), 2) miR34a mimic + Vehicle, 3) miR34a mimic + trametinib.

Serum Creatinine Measurement.
Serum creatinine (SCr) was determined using the Creatinine Enzymatic Reagent Assay
kit (Pointe Scientific, Canton, MI) [c7548-120] based on the manufacturer’s directions.
All values are expressed as serum creatinine concentration in milligrams per deciliter.

RT-qPCR Analysis of mRNA and microRNA Expression.
Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life
Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used
according to the manufacturer’s protocol. The generated cDNA was used with the
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA
expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA
and rabbit tubulin RNA were used as reference genes for normalization (see Table 1 for
Primer pairs). For microRNA the MystiCq microRNA cDNA synthesis kit was used
according to the manufacturer’s instructions (Sigma-Aldrich) [MIRRT]. MystiCq
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SYBR green (Sigma-Aldrich) [MIRRM00] and universal PCR primer (Sigma-Aldrich)
[MIRUP] were used for RT-qPCR. The relative microRNA expression was determined
by the 2−ΔΔCt method, and the mouse small nucleolar RNA, SNORD48 was used as a
reference small non-coding RNA for normalization (Sigma-Aldrich) [MIRCP00007].
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Immunoblot Analysis.
Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4). Protease
inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium orthovanadate
(Sigma-Aldrich) and nicotinamide and 4-phenylbutyrate were added fresh before each
extraction.
Equal protein quantities (10–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved
by gel electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad).
Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and
incubated overnight with primary antibody at 4°C with gentle agitation. Primary
antibodies used in these studies included phospho-ERK1/2 (1:1000) [#4370], total
ERK1/2 (1:1000) [#4695]. β-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX) [ sc47778].
Membranes were incubated with the appropriate horseradish peroxidase–conjugated
secondary antibody before visualization using enhanced chemiluminescence (Thermo
Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was
determined using the ImageJ software from NIH and Image Studio Lite from LI-COR.

Immunoprecipitation.
Following protein extraction, protein quantification was performed using Pierce 660 nm
Assay (ThermoFisher Scientific) [22660]. Equal amounts of protein from every group
were utilized according to the instructions from Dynabeads Protein G
Immunoprecipitation Kit (ThermoFisher Scientific). Immunoprecipitation was
139

performed using acetylated-lysine antibody (1:100; Cell Signaling) [#9441]. PGC-1α
antibody (1:1000; abcam) [ab54481] was used for immunoblotting pull-down and input.
Veriblot (1:400; abcam) [ab131366] was used for detection of immunoblotted target
protein before visualization using enhanced chemiluminescence (Thermo Scientific)
and the GE ImageQuant LAS4000 (GE Life Sciences).

Respirometry Assay:
Oxygen consumption rate (OCR) was determined using a Seahorse Bioscience XF-96
instrument as previously described (20465991). RPTC were plated at 18,000 cells per
well and grown for 36 hr before a 24 hr treatment. The XF-96 protocol consists of five
measurements of basal OCR (1 measurement/2.5 min), injection of carbonyl cyanide-4(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma) [#C2920], and four measurements
of uncoupled OCR (1 measurement/2.5 min).

NAD+ and NADH measurement.
Quantification of NAD+ and NADH were carried out using the NAD/NADH Assay Kit
(abcam) [#ab65348] according to the manufacturer's instructions. NAD+ and NADH
values were normalized to kidney cortex wet weight.

NAMPT Activity Assay.
To quantify the enzymatic activity of NAMPT in kidney cortex, protein extracts were
assayed according to the manufacturer’s instructions using the Cyclex NAMPT
Colorimetric Assay Kit (MBL International) [#CY-1251].
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Statistical Analysis.
All data are shown as mean ± S.E.M. When comparing two experimental groups, an
unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical
differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc
test was performed for comparisons of multiple groups. P < 0.05 was considered
statistically significant. All statistical tests were performed using GraphPad Prism
software (GraphPad Software, San Diego, CA).
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RESULTS
ERK1/2 Inhibition Prevents IR-Induced Downregulation of PGC-1α and
Downstream MB Targets, and Attenuates Kidney Dysfunction.
The effect of ERK1/2 activation and inhibition on PGC-1α signaling in the renal cortex
24 hr after renal IR injury was examined. We previously demonstrated the potent and
selective MEK1/2 inhibitor trametinib blocks ERK1/2 activation in this model [10] and
confirmed ERK1/2 phosphorylation increased in the IR group and was blocked by
trametinib, without a change in total ERK1/2 (Figure 4.1A). PGC-1α mRNA and
protein decreased ~70% and ~55%, respectively, 24 hr after IR injury (Figure 4.1 B,C).
Pretreatment with trametinib 1 hr before IR injury partially prevented this decrease in
PGC-1α mRNA and protein at 24 hr (Figure 4.1 B,C). MB proteins involved in PGC1α signaling and the mitochondrial electron transport chain such as nuclear-encoded
NDUFS1 and NDUFB8, and the mitochondrial-encoded COX1 decreased after IR
injury and were completely attenuated by trametinib pretreatment (Figure 4.1 A,B).
Specific downstream transcriptional targets of PGC-1α, including TFAM, superoxide
dismutase 2 (SOD2), and forkhead box protein O1 (FOXO1) mRNA, that were
previously demonstrated to be regulated by ERK1/2 [10] were reduced ~70% after 24 hr
and was partially attenuated by trametinib (Figure 4.1 C). In addition, the renal
dysfunction marker, serum creatinine, increased ~10-fold after IR and trametinib
completely prevented the increase in serum creatinine, and the loss of renal function in
response to IR injury (Figure 4.1 D). PGC-1α signaling has been shown to play a
critical role in MB, and preventing and restoring renal function in settings of AKI [10,
25, 31, 38]. MB proteins and mRNA were consistently decreased 24 hr after injury and
142

trametinib pretreatment partially or completely prevented the decreases, ultimately,
preventing a rise in serum creatinine.
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Figure 4.1: ERK1/2 Inhibition Prevents IR-Induced Downregulation of PGC-1α
and Downstream MB Targets, and Attenuates Kidney Dysfunction. A)
Representative immunoblot of phosphorylated ERK1/2 and PGC-1α following 24 hr
of IR AKI. B) Densitometry analysis of PGC-1α, NDYFS1, NDUFB8 and COX1.
C) PGC-1α mRNA expression following IR AKI after 24 hr. D) Serum creatinine
was assessed 24 hr after IR AKI. Data are represented as mean ± S.E.M., n ≥ 4.
Different superscripts indicate statistically significant differences (P < 0.05), where
‘b’ is different from ‘a’ and ‘c’ is different from ‘a’ and ‘b’.
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ERK1/2 Inhibition Attenuates PGC-1α Acetylation Increases Following 24 hr AKI.
Because PGC-1α acetylation status alters its activity, particularly following an acute
injury [39-42], we used acetylated-lysine immunoprecipitation to look at PGC-1α
acetylation. In the IR group, PGC-1α was more acetylated, meaning less active,
compared to the sham group (Figure 4.2 A). However, in the trametinib + IR group
there was less acetylated PGC-1α compared to the IR group and not different than the
sham group (Figure 4.2 A). PGC-1α is a major target of deacetylation [43, 44] for the
NAD-dependent deacetylase, SIRT1. SIRT1 deacetylation of PGC-1α has been
reported to play a critical role during AKI [39, 40]. After IR injury SIRT1 protein was
decreased and this decrease was prevented in the trametinib + IR group (Figure 4.2 B).
SIRT1 mRNA was downregulated at 24 hr after IR injury and was not altered in the
trametinib + IR group (Figure 4.2 B). These results reveal that trametinib pretreatment
preserves PGC-1α in a more active state by preventing PGC-1α acetylation following
24 hr IR injury and may be explained by the prevention of SIRT1 protein loss due to
trametinib.
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Figure 4.2: ERK1/2 Inhibition Attenuates PGC-1α Acetylation Increases
Following 24 hr AKI. A) Representative immunoblot of PGC-1α following IP of
acetylated lysine. B) Representative immunoblot of SIRT1, and analysis of SIRT1
protein and mRNA. Data are represented as mean ± S.E.M., n ≥ 4. Different
superscripts indicate statistically significant differences (P < 0.05).
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ERK1/2 Inhibition Attenuated NAD+ Loss After 24 hr IR Injury but Not at 3 hr.
As SIRT1 enzymatic activity is dependent on the availability of cellular NAD+, we
examined the effect of ERK1/2 activation and inhibition on NAD+ metabolism in the
renal cortex following renal IR injury [45]. At 3 and 24 hr after renal IR injury
trametinib pretreatment blocked ERK1/2 phosphorylation (Figure 4.1 A; Fig 4.3 A).
NAD+ and NADH did not change at 3 hr following IR injury in any group, however the
ratio trended up in the trametinib + IR group (Figure 4.3 B-D). At 24 hr, NAD+ and
NADH decreased ~50% with no change in the NAD+:NADH ratio in response to IR
injury alone (Figure 4.3 E-G). Pretreatment with trametinib 1 hr before IR injury
partially prevented the decrease of NAD+ without a change in NADH loss, resulting in a
marked increase in the NAD+:NADH ratio (Figure 4.3 E-G). These results reveal that
ERK1/2 plays a role in NAD+ metabolism during IR injury and inhibiting ERK1/2
attenuates the NAD+ loss.
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Figure 4.3: ERK1/2 Inhibition Attenuated NAD+ Loss After 24 hr IR Injury
but Not at 3 hr. A) Representative immunoblot of pERK1/2 and tERK1/2 after IR
AKI at 3 hr. B, C, E, F) NAD+ and NADH Measurement after IR AKI at 3 and 24
hr in renal cortex. D, G) Ration of NAD+/NADH analyzed after IR AKI at 3 and
24 hr. Data are represented as mean ± S.E.M., n ≥ 5. Different superscripts
indicate statistically significant differences (P < 0.05).
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ERK1/2 Activation Following IR Decreases NAMPT Protein and Trametinib
Prevents IR-Induced NAMPT Loss.
To elucidate the mechanism of ERK1/2-mediated NAD+ and NADH loss in renal IR
injury, protein and mRNA levels of the enzymes responsible for NAD+ biosynthesis
were measured (Fig 4.7 -Visual abstract). NAMPT protein was measured 3 and 24 hr
after IR injury and no change was observed at 3 hr (Figure 4.4 A); however, at 24 hr
NAMPT protein was decreased 50% compared to sham mice (Figure 4.4 B, C).
Trametinib pretreatment increased NAMPT protein compared to the IR group at 3 hr
(Figure 4.4 A), and at 24 hr prevented the NAMPT protein loss observed in the IR
group (Figure 4.4 B, C).
Protein levels for the three enzymes responsible for conversion of NMN to NAD+
revealed that only NMNAT1 was decreased in the IR group and that trametinib
prevented this decrease (Figure 4.4 B, C). NMNAT2 and NMNAT3 proteins were not
changed in the IR group nor trametinib + IR group (Figure 4.4 B, C). The activity of
NAMPT did not change in the IR and trametinib + IR group compared to sham activity
(Figure 4.4 E). These results reveal that ERK1/2 inhibition increases NAMPT early
after IR injury and prevents NAMPT and NMNAT1 protein loss 24 hr after IR injury.
As both NAMPT and NMNAT1 contribute to NAD synthesis, and NAMPT is the ratelimiting enzyme in the salvage pathway (Figure 4.7 - Visual abstract) [46], and the
salvage pathway is responsible for greater than 99% of the total NAD synthesis [30],
ERK1/2 mediated NAD+ loss is the result of NAMPT and NMNAT1 protein loss.
To determine if the decrease in NAMPT and NMNAT1 proteins was the result of
decreased transcription, mRNA of the respective proteins were measured. Both vehicle
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and trametinib-treated IR groups exhibited ~60% reduction in NAMPT and NMNAT1
mRNA at 24 hr (Figure 4.4 D). Thus, ERK1/2 inhibition did not restore NAMPT and
NMNAT1 mRNA but did restore protein (Figure 4.4 C), suggesting that ERK1/2
regulates these enzymes independent of transcription. Other NAD+ salvage enzymes,
NMNAT3 and NRK1, and the important NAD de novo enzyme, QPRT, also exhibited
marked decreases in mRNA levels in the IR and trametinib + IR groups [47] (Figure 4.4
D). These results demonstrate that following IR injury the synthesis of key NAD+
metabolizing enzyme mRNA are substantially decreased.
The microRNA, miR34a, can directly bind to the 3’-UTR of NAMPT mRNA and
regulate NAMPT protein expression, and are inversely correlated [48]. Because
NAMPT protein was increased at 3 hr and attenuated at 24 hr in the trametinib + IR
group (Figure 4.4 A,B), miR34a was measured. At 3 hr miR34a levels decreased in the
trametinib + IR group and were not altered in the 3 hr IR group (Figure 4.4 F). At 24 hr
following IR injury, miR34a levels were still decreased in the trametinib + IR group
compared to the sham and IR groups (Figure 4.4 G). These results correlate increased
NAMPT protein when ERK1/2 is inhibited to decreased miR34a.
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Figure 4.4: ERK1/2 Activation Following IR Decreases NAMPT Protein and
Trametinib Prevents IR-Induced NAMPT Loss. A) Representative immunoblot
and densitometry of NAMPT after IR AKI at 3 hr. B) Representative immunoblot
of NAMPT, NMNAT1,2,3 after IR AKI at 24 hr. C) Densitometry analysis of
NAMPT. D) mRNA expression measured for NAD biosynthetic pathway
enzymes. E) Activity of NAMPT. F-G) miR34a expression measured after IR AKI
at 3 and 24 hr. Data are represented as mean ± S.E.M., n ≥ 5. Different
superscripts indicate statistically significant differences (P < 0.05).
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ERK1/2 Physiologically Regulates miR34a. ERK1/2 Inhibition Decreases miR-34a,
leading to increases in NAMPT Protein.
To examine if ERK1/2 also regulates miR34a and NAMPT protein at a physiological
level we administered trametinib to naïve mice. Following a 4 hr trametinib treatment,
ERK1/2 phosphorylation was completely inhibited in the renal cortex (Figure 4.5A).
NAMPT protein increased 44% in the trametinib group compared to the control group,
and NAMPT mRNA did not change (Figure 4.5A, B). Concurrently, miR34a expression
decreased 40% in the trametinib treated group (Figure 4.5B). Interestingly, NAD+ and
NADH were not altered in response to the increased NAMPT protein (Figure 4.5C).
These data reveal that ERK1/2 affects NAMPT and miR34a under physiological
conditions and does so without changing NAD+ and NADH content in mouse renal
cortex.
To investigate whether ERK1/2 inhibition-induced increase in NAMPT protein is
miR34a dependent, we utilized a miR34a mimic to prevent trametinib-induced decrease
of miR34a. Naïve mice were treated with a mirVana miR34a mimic mixed with in vivojetPEI via retro-orbital injection to prevent trametinib treatment from decreasing
miR34a [49]. The miR34a mimic increased miR34a levels in both the 34a mimic group
and in the 34a mimic + trametinib group at least two-fold compared to vehicle (Figure
4.5D). Increasing miR34a levels in the cortex was not only able to prevent trametinibinduced NAMPT protein upregulation but also minimally decreased NAMPT protein in
both the miR34a mimic group and the 34a + trametinib group (Figure 4.5E, F). In
summary, ERK1/2 phosphorylation appears to regulate miR34a, and inhibition of
ERK1/2 phosphorylation decreases miR34a, which leads to an increase in NAMPT
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protein. This ERK1/2/miR34a/NAMPT pathway is prevented by increasing miR34a
levels using a miR34a mimic, which prevented the trametinib-induced increase in
NAMPT protein expression.
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Figure 4.5: ERK1/2 Physiologically Regulates miR34a and ERK1/2 Inhibition
Decreases miR-34a, leading to increases in NAMPT Protein. A) Representative
immunoblot of pERK1/2, and NAMPT protein 4 hr after trametinib
administration. B) Densitometry analysis of NAMPT protein, and mRNA and
miRNA expression measurements of NAMPT and miR34a at 4 hr after trametinib
treatment. C) NAD+ and NADH content in renal cortex measured at 4 hr after
trametinib treatment. D) miR34a expression after 34a mimic treatment in mice. E)
Representative immunoblot of NAMPT protein after 34a mimic treatment in renal
cortex. F) Densitometry analysis of NAMPT protein after 34a Mimic treatment.
Data are represented as mean ± S.E.M., n ≥ 5. Different superscripts indicate
statistically significant differences (P < 0.05).
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Trametinib-Induced Prevention of Serum Creatinine Elevation Following IR is
Dependent on NAMPT Activity.
Because ERK1/2 inhibition increased NAMPT protein in a miR34a dependent pathway
we sought to clarify the role that NAMPT protein contributes to trametinib-induced
prevention of serum creatinine elevation in IR-induced AKI. We utilized the NAMPT
inhibitor, FK866, [50, 51] and mice were pretreated before IR surgery with either
vehicle or FK866 20 mg/kg [36]. Mice pretreated with trametinib were protected from
IR-induced serum creatinine increases compared to the Veh + IR group (Figure 4.6 A).
Mice pretreated with FK866 and subjected to IR exhibited did not have any effect on
increased serum creatinine in the Veh + IR group. In contrast, mice pretreated with both
FK866 and trametinib had the same increase in serum creatinine as the Veh + IR and
FK866 + IR groups, and reversed the protective effect of trametinib (Figure 4.6 A).
These results provide evidence that ERK1/2 inhibition by trametinib protects against
IR-induced serum creatinine elevation after 24 hr by maintaining NAMPT and
preventing NAD+ decline following IR.
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Figure 4.6: Trametinib-Induced Prevention of Serum Creatinine Elevation
Following IR is Dependent on NAMPT Activity. A) Serum creatinine
measurements following pretreatment with trametinib, FK866, and a combo of
FK866 and trametinib after IR AKI at 24 hr. Data are represented as mean ±
S.E.M., n ≥ 4. Different superscripts indicate statistically significant differences (P
< 0.05).
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Figure 4.7: Visual Abstract. Proposed mechanism of trametinib-induced
prevention of renal dysfunction following IR injury.
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DISCUSSION
We have previously studied the role of ERK1/2 in PGC-1α signaling under
physiological and pathological conditions and determined that early activation of
ERK1/2 following renal IR injury was responsible for the initial decrease in PGC-1α
mRNA expression, and correlated with kidney dysfunction [10]. Here, we have
expanded our studies to understand the connection between ERK1/2 and NAD+
regulation under physiological and renal IR conditions, and in context with PGC-1α
signaling. We determined that inhibition of ERK1/2 activation decreased miR34a, the
microRNA regulator of both SIRT1 and NAMPT (Figure 4.7). The decrease in miR34a
led to an increase in NAMPT protein under control conditions and attenuated the loss of
NAMPT and SIRT1 after renal IR injury. Prevention of NAMPT loss attenuated
decreases in NAD+ following IR injury, and prevented PGC-1α acetylation through
activation of SIRT1. Furthermore, this trametinib-induced miR34a/NAMPT regulation
was prevented by pretreatment with a miR34a mimic, indicating increased NAMPT
protein expression by ERK1/2 inhibition was dependent on miR34a.

Similar to our miR34a results, Choi SE et al., observed NAMPT protein regulation by
miR34a in the liver of obese mice [48]. Hepatic NAMPT protein was lower in obese
mice compared to controls, and was regulated by an increase in miR34a. SIRT1 was
also shown to correspond with miR34a levels, as miR34a can bind to and repress
NAMPT and SIRT1 mRNA translation [48, 52, 53]. ERK1/2 regulation of miR34a has
not been well characterized; however, a few studies demonstrated that ERK1/2
phosphorylation is reduced as a result of a rise in miR34a expression [54, 55]. In liver
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cancer, active ERK1/2 was shown to phosphorylate exportin-5, which led to a decrease
in pre-miRNA export from the nucleus and a global reduction in miRNA [56].
However, a regulatory connection between a decrease in phosphorylated ERK1/2 and a
decrease in miR34a expression, as reported in this study, has not been elucidated.

Because NAMPT protein increased at 4 hr after trametinib administration without any
change in NAMPT mRNA, we conclude ERK1/2 inhibition rapidly decreases miR34a
in the renal cortex and subsequently, induces an increase in NAMPT protein. Because
NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway, and proximal
tubules have been shown to have a high abundance of NAMPT [46, 57, 58], any
prevention of the loss of this enzyme has the potential to directly impact the NAD+
content and severity of the injury. As both Tran et al. and Guan et al. demonstrated
within the kidney, NAD+ levels can directly influence AKI susceptibility [31, 33].
However, this is not a kidney-specific phenomenon, as NAD+ boosting or pathway
upregulation has been shown to have positive health outcomes relating to multiple
organs, including the liver, heart, pancreas, skeletal muscle, brain, and nervous system
[59-66].

NAD+ and NADH were not altered when NAMPT protein increased at 4 hr possibly
demonstrating the salvage pathway maintains only a fixed NAD+ level physiologically
without the addition of NAD precursors. However, during an acute renal injury, we
found that preventing the loss of NAMPT protein led to an attenuation of the NAD+
decline at 24 hr following IR injury. In addition, using the NAMPT inhibitor, FK866,
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we found trametinib treatment did not prevent an increase in serum creatinine if given
in combination with FK866.

Trametinib administration prevented ERK1/2 phosphorylation in uninjured and IR
injured renal cortical tissue. PGC-1α expression decreased following IR injury at 24 hr,
which trametinib pretreatment attenuated. PGC-1α acetylation increased following IR
injury in mice, which decreases PGC-1α transcriptional co-activator activity [43, 67].
Our group has previously demonstrated the SIRT1 activator SRT1720, in an AKI
model, increased the deacetylation status of PGC-1α allowing for more effective
recruitment of various transcription factors that stimulate the expression of downstream
target genes [39, 43]. Here, we demonstrate the same concept using trametinib, and
observed an increase in deacetylated PGC-1α in the trametinib mice following IR injury
and an increase in MB associated proteins, including NDUFS1, NDUFB8, and COX1.
Furthermore, trametinib pretreatment prevented the rise in serum creatinine at 24 hr
post IR injury observed in the vehicle-treated group.
Because trametinib altered the acetylation status of PGC-1α and increased PGC-1α
downstream targets of MB, SIRT1 and the necessary coenzyme for SIRT1 enzymatic
activity, NAD+, were further studied. The increase in deacetylated PGC-1α due to
trametinib administration was discovered to likely stem from the attenuation of the
decrease in SIRT1 protein and NAD+ content following IR injury. The availability of
NAD+ is directly linked to the activity of SIRT1, therefore having more SIRT1 and
NAD+ available in the trametinib group prevented a decrease in SIRT1 activity
following IR injury [44, 45, 68].
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An increase of PGC-1α in a renal tubule inducible PGC-1α transgenic mouse model
upregulated the enzymes of the de novo NAD biosynthetic pathway [31]. The opposite
was found as a decrease in PGC-1α suppressed the enzymes of the NAD biosynthetic
pathway, as observed in both Pgc1α−/− uninjured kidneys and WT IR kidneys [31]. We
observed similar results in our studies where PGC-1α is downregulated and NAD
content is decreased after renal IR injury ([10] and present). Better renal functional
outcomes were observed in the PGC-1α transgenic mice compared to controls, and
worse outcomes were observed in the Pgc1α−/− mice, linking PGC-1α and NAD to AKI
severity. Here, a decrease in PGC-1α protein and PGC-1α acetylation, prevented renal
dysfunction as measured by serum creatinine.

These experimental results have identified three important findings: 1) Confirmation of
ERK1/2 inhibition before IR AKI attenuates the downregulation of PGC-1α and certain
MB targets, 2) ERK1/2 inhibition is able to decrease miR34a levels acutely leading to
SIRT1 and NAMPT increases, 3) NAMPT protein is vital for ERK1/2 inhibitioninduced reduction in IR AKI severity (Figure 1A). In addition, trametinib pretreatment
prevented ERK1/2 phosphorylation and attenuated kidney dysfunction as measured by
serum creatinine at 24 hrs following IR AKI. ERK1/2 inhibition attenuated decreases in
PGC-1α protein, PGC-1α acetylation, and specific downstream MB targets, SIRT1 and
NAMPT protein, and NAD+ after IR injury.
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CHAPTER FIVE:
Future Directions for ERK1/2-Mediated Mitochondrial Biogenesis Signaling
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Elucidating the EGFR Ligand Responsible for ERK1/2-Mediated MB Signaling
While ERK1/2-mediated MB was elucidated in the scope of this project, there are
additional questions that remain unanswered. We used the MEK1/2 inhibitor,
trametinib, to prevent ERK1/2 activation as a consequence of IR injury. By doing so we
observed a prevention in the downregulation of PGC-1α and PGC-1α downstream gene
targets. Not only did trametinib pretreatment prevent the negative regulation of PGC1α, it prevented a rise in serum creatinine. In chapter two, we made the observation that
the EGFR inhibitor, erlotinib, also inhibited ERK1/2 phosphorylation. The inhibition of
ERK1/2 phosphorylation using erlotinib was not as strong as the treatment with
trametinib, yet, we observed very similar downstream effects. By blocking ERK1/2
phosphorylation thru inhibiting the EGFR, we increased PGC-1α and NRF1 mRNA in
our cultured primary rabbit renal proximal tubule cells (RPTC), again, very similar to
our observation with trametinib. Erlotinib administration to naïve mice decreased
ERK1/2 activation and increased PGC-1α mRNA, even at a physiological level.

Interestingly, pretreatment with erlotinib blunted the increase in ERK1/2
phosphorylation typically seen following IR injury in the renal cortex. We observed a
prevention of PGC-1α mRNA downregulation, as well as an increase in PGC-1α
protein. Most importantly, this prevention of negative PGC-1α regulation after IR
injury, prevented a rise in serum creatinine similar to trametinib. It should be noted the
prevention of the rise of serum creatinine was not as great in the erlotinib groups
compared to the trametinib groups, but was significant from vehicle + IR group. These
findings are in contrast to some studies which has suggested EGFR inhibition or the use
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of waved-2 mice (mice with reduced EGFR tyrosine kinase activity), actually causes
worsening kidney damage and dysfunction following injury [1-3]. The observation is
that EGFR inhibition prevents tubule dedifferentiation and proliferation. Our studies
were not setup to examine those biological functions, however, a one-time dose of
erlotinib prior to IR injury leading to AKI, seems to be beneficial in the acute phase.
With only a single dose, however, the drug would be out of the circulatory system in ~
24 hr, possibly preventing any dedifferentiation and proliferation effects observed in
other studies. This contrast in studies brings up an interesting concept, in that global
inhibition of EGFR signaling may not be the best tactic for preventing AKI.

Because we observed similar downstream prevention of PGC-1α and PGC-1α related
genes in both our trametinib and erlotinib groups, yet erlotinib did not block ERK1/2
phosphorylation to the extent trametinib did, there may be a specific ligand that is
causing the negative regulation of PGC-1α and related MB targets following IR injury.
In other words, there may be a specific ligand that binds to EGFR and causes ERK1/2
phosphorylation that is the driving force to negatively regulate PGC-1α and downstream
MB targets. Therefore, my first future project experiments would focus on finding the
EGFR ligand responsible for ERK1/2 activation at the initiation of IR injury.

These projects would potentially help identify a pharmacological target more specific
for pre-treatment before surgeries known to cause renal dysfunction (ex. cardiac
surgeries). Inhibiting one specific ligand versus inhibiting MEK1/2 or the EGFR would
be more specific, possibly have less side effects, and contribute to less organ system
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alterations in patients with other disease states. Another possible benefit of identifying
one specific ligand that prevents the same downregulation of PGC-1a as ERK1/2
inhibition is that the ligand inhibitor may be druggable beyond a one-time pretreatment
dose.

Studies have shown consistent ERK1/2 inhibition following AKI is detrimental and
worsens kidney function [4-7]. There are only seven known EGFR ligands [8] : 1)
epidermal growth factor (EGF), 2) transforming growth factor-alpha (TGFA), 3)
heparin-binding EGF-like growth factor (HB-EGF), 4) betacellulin (BTC), 5)
amphiregulin (AREG), 6) epiregulin (EREG), 7) epigen (EPGN). Most EGFR ligands
are upregulated rapidly following renal insult and activate the EGFR through membrane
bound or cleaved interactions [3, 9, 10]. EGFR ligands are cleaved by proteases and a
disintegrin and metalloproteinase (ADAMs) [11, 12]. Some preliminary experiments
using our RPTC cultures has shown that broadly inhibiting matrix metalloproteinase
(MMPs) using the compounds, marimistat and TAPI-2, we get partial inhibition of
ERK1/2 phosphorylation [13, 14], as seen in the figures below (Figure 5.1 and Figure
5.2).
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Figure 5.1: Broad MMP inhibition, using TAPI-2, decreases ERK1/2
phosphorylation at 4 and 24 hr after dosing in RPTC culture.
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Figure 5.2: Marimistat decreases ERK1/2 phosphorylation at 4 hr
after dosing in RPTC culture.
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Mitochondrial Supercomplexes in Relation to Pharmacological Activation of MB
Our lab has previously demonstrated that pharmacological activation of MB in our
RPTC cultures increases PGC-1α and downstream MB targets at a mRNA and protein
level. A phenotypic marker of our MB pharmacological agents is an increase in oxygen
consumption after the addition of a proton uncoupling agent (FCCP) as measured by the
Seahorse XF96 Analyzer [15]. By measuring oxygen consumption rate following
FCCP, we are mimicking how well the mitochondria can handle an injury or outside
stressor. The higher the oxygen consumption rate the more new mitochondria generated
following pharmacological treatment, or the more efficient the current mitochondria are
due to increased electron transport proteins [15-17].

Recently, the electron transport chain (ETC) assembly has been investigated to observe
the various complexes of the ETC and how they interact with each other. The ETC
assembly can be static or dynamic, and these complex interactions following injury are
altered. The term mitochondrial supercomplexes is used to denote ETC complex I, II,
III, IV, and cytochrome c assembling together as one complex assembly instead of
multiple individual complexes [18]. As seen below, ETC complexes can be assembled
into one supercomplexes [19] (Figure 5.3). Mitochondrial supercomplexes with various
configurations and stoichiometries occur in mitochondria from different sources [2024]. However, alterations in mitochondrial supercomplex formation following treatment
with pharmacological agents that induce renal MB at a physiological and pathological
level, has not been elucidated.
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MB and mitochondrial supercomplex assembly enhances many of the same biological
pathways. Mitochondrial supercomplex formation has been shown to enhance
mitochondrial efficiency, increase respiratory reserve capacity, increase ATP
production, lower ROS formation, is altered after ischemic injury, and declines with age
[25-28]. The above-mentioned phenomena are all similar to observations made with
increased PGC-1α and MB, along with a decline following injury and with age [29-32].
Mitochondrial supercomplex assembly was observed following 24 hr IR injury with a 1
hr pretreatment with vehicle or trametinib (1mg/kg). Figure 5.4 depicts the gel, PVDF
membrane, and immunoblot for mitochondrial complexes following a modified bluenative PAGE (BN-PAGE) experiment. Figure 5.5 shows side-by-side a mitochondrial
supercomplex BN-PAGE from a review article next our experimental BN-PAGE
following 24 hr IR. No quantifications were performed, however, two supercomplexes,
complex V assembled with complex III 2 + IV 1 and complex III 2 + IV 2 , look to be
increased in the 24 hr IR group, whereas the trametinib treated animals have those
supercomplexes levels similar to sham. This increase in supercomplex formation in the
IR group may be a compensatory mechanism in which the damaged cortex needs to be
as efficient as possible. The trametinib treated animal are not as injured, as previously
shown in chapter 2 and chapter 4. Therefore, supercomplex formation may not be
required at 24 hr following IR injury because the scope of the injury does not dictate the
increased formation of supercomplexes.

Timing may play a crucial role in mitochondrial supercomplex formation following
injury. As we have only performed a 24 hr time point, much more work following IR
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injury would need to done to outline a timing pathway in response to IR injury. Various
supercomplexes may be favored during different time points after IR injury and
depending on the severity of the injury [33, 34]. Alterations in these supercomplexes
following administration of a pharmacological agent that induces MB would be of
interest to further enhance the identification of a pharmacological agent that has the
potential for therapeutic use for treatment of AKI.
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Figure 5.3: A) Mitochondrial electron transport chain complexes depicted in
a non-supercomplexes state. B) Mitochondrial supercomplexes assembly.
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Figure 5.4: A) Tris-glycine gel following BN-PAGE using isolated
mitochondria from the renal cortex of mouse kidneys. B) PVDF
membrane following BN-PAGE modified protocol. C) Immunoblot of
PVDF membrane after incubation with mitochondrial complex
antibodies. Further clarification can be found in figure 5.5.
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Figure 5.5: Immunoblot of PVDF membrane after modified BN-PAGE
and incubation with mitochondrial complex antibodies. Next to our image
is a representative mitochondrial supercomplex image pulled from an
instructional review by Auwerx, et al. Adapted from (26928661)
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